Tokushima University / Educator and Researcher Directory --- ANDO, Hidenori

Personal Web Page

https://researchmap.jp/canther (researchmap)

Field of Study

○	Life sciences [Clinical pharmacy]
○	Life sciences [Clinical pharmacy]
○	Life sciences [Clinical pharmacy]

Subject of Study

Book / Paper

Book:

1.	田島健次, 松島得雄, 小瀬亮太, 藤田彩華, 甲野裕之, Hidenori ANDO and Tatsuhiro Ishida : ナノフィブリル化バクテリアセルロースの生産とその応用, NTS Inc., Nov. 2021.
2.	Tatsuhiro Ishida and Hidenori ANDO : ドラッグデリバリーシステム(DDS), 京都廣川書店, 2015.

Academic Paper (Judged Full Paper):

1.	Eiichiro Kaneko, Haruto Tsujisaki, Masashi Fujiwara, Hidenori ANDO, Yasushi Sato, Tatsuhiro Ishida, Hirofumi Tani and Kenji Tajima : Application of bacterial-derived long cellulose nanofiber to suspension culture of mammalian cells as a shear protectant, International Journal of Biological Macromolecules, Vol.280, No.3, 135938, 2024. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijbiomac.2024.135938 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.ijbiomac.2024.135938 (DOI: 10.1016/j.ijbiomac.2024.135938)
2.	Taiki Hori, Taro Shimizu, Hidenori ANDO, Naoto Okada, Hiroki Yamagami, Saya Yasui, Minae Hosoki, Akihiro Tojima, Toshiki Otoda, Tomoyuki Yuasa, Ken-ichi Aihara, Makoto Takishita, Sumiko Yoshida, Masahiro Abe, Tatsuhiro Ishida and Shingen Nakamura : Humoral immune response against SARS-CoV-2 and polyethylene glycol elicited by anti-SARS-CoV-2 mRNA vaccine, and effect of pre-existing anti-polyethylene glycol antibody in patients with hematological and autoimmune diseases., Heliyon, Vol.10, No.10, e31489, 2024. (Summary) The effects of vaccination are modified by hematological and autoimmune diseases and/or treatment. Anti-SARS-CoV-2 mRNA vaccine contains polyethylene glycol (PEG), it is largely unknown whether PEG influences the effects of vaccination or induces a humoral response. This study examined whether anti-PEG antibodies before vaccination (pre-existing) influenced the acquisition of SARS-CoV-2 antibodies and evaluated the relationship between the development of anti-SARS-CoV-2 antibodies and anti-PEG antibodies after SARS-CoV-2 vaccination in hematological and autoimmune diseases. Anti-SARS-CoV-2 antibody IgG, anti-PEG IgG, and IgM titers were evaluated in patients with hematological and autoimmune diseases after the second dose of BNT162B2. Anti-PEG IgG and IgM titers were also measured before vaccination to examine changes after vaccination and the relationship with vaccine efficacy. In patients with hematological (n = 182) and autoimmune diseases (n = 96), anti-SARS-CoV-2 and anti-PEG antibody titers were evaluated after a median of 33 days from 2nd vaccination. The median anti-SARS-CoV-2 antibody titers were 1901 AU/mL and 3832 AU/mL in patients with hematological and autoimmune disease, respectively. Multiple regression analysis showed that age and days from 2nd vaccination were negatively associated with anti-SARS-CoV-2 antibody titers. Anti-CD20 antibody treatment was negatively correlated with anti-SARS-CoV-2 antibody titers in hematological disease, and C-reactive protein (CRP) was positively correlated with anti-SARS-CoV-2 antibody titers in autoimmune disease. Baseline anti-PEG antibody titers were significantly higher in patients with autoimmune disease but were not correlated with anti-SARS-CoV-2 antibody titers. Patients with increased anti-PEG IgG acquired higher anti-SARS-CoV-2 antibody titers in patients with autoimmune disease. Anti-SARS-CoV-2 antibody acquisition was suboptimal in patients with hematological disease, but both anti-SARS-CoV-2 antibody and anti-PEG IgG were acquired in patients with autoimmune disease, reflecting robust humoral immune response. Pre-existing anti-PEG antibody titers did not affect anti-SARS-CoV-2 antibody acquisition. (Tokushima University Institutional Repository) ● Metadata: 119625 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.heliyon.2024.e31489 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38813140 ● Search Scopus @ Elsevier (PMID): 38813140 ● Search Scopus @ Elsevier (DOI): 10.1016/j.heliyon.2024.e31489 (Tokushima University Institutional Repository: 119625, DOI: 10.1016/j.heliyon.2024.e31489, PubMed: 38813140)
3.	Gaballa A Sherif, Taro Shimizu, Haruka Takata, Hidenori ANDO, Ibrahim Mohamed, Emam Emam Abdallah Sherif, Nana Amorim Cristina Matsuo, Yuri Kim, Naguib W Youssef, Mady M Fatma, Khaled A Khaled and Tatsuhiro Ishida : Impact of anti-PEG IgM induced via the topical application of a cosmetic product containing PEG derivatives on the antitumor effects of PEGylated liposomal antitumor drug formulations in mice, Molecular Pharmaceutics, Vol.21, No.2, 622-632, 2024. (Summary) Poly(ethylene glycol) (PEG) is used in many common products, such as cosmetics. PEG, however, is also used to covalently conjugate drug molecules, proteins, or nanocarriers, which is termed PEGylation, to serve as a shield against the natural immune system of the human body. Repeated administration of some PEGylated products, however, is known to induce anti-PEG antibodies. In addition, preexisting anti-PEG antibodies are now being detected in healthy individuals who have never received PEGylated therapeutics. Both treatment-induced and preexisting anti-PEG antibodies alter the pharmacokinetic properties, which can result in a subsequent reduction in the therapeutic efficacy of administered PEGylated therapeutics through the so-called accelerated blood clearance (ABC) phenomenon. Moreover, these anti-PEG antibodies are widely reported to be related to severe hypersensitivity reactions following the administration of PEGylated therapeutics, including COVID-19 vaccines. We recently reported that the topical application of a cosmetic product containing PEG derivatives induced anti-PEG immunoglobulin M (IgM) in a mouse model. Our finding indicates that the PEG derivatives in cosmetic products could be a major cause of the preexistence of anti-PEG antibodies in healthy individuals. In this study, therefore, the pharmacokinetics and therapeutic effects of Doxil (doxorubicin hydrochloride-loaded PEGylated liposomes) and oxaliplatin-loaded PEGylated liposomes (Liposomal l-OHP) were studied in mice. The anti-PEG IgM antibodies induced by the topical application of cosmetic products obviously accelerated the blood clearance of both PEGylated liposomal formulations. Moreover, in C26 tumor-bearing mice, the tumor growth suppressive effects of both Doxil and Liposomal l-OHP were significantly attenuated in the presence of anti-PEG IgM antibodies induced by the topical application of cosmetic products. These results confirm that the topical application of a cosmetic product containing PEG derivatives could produce preexisting anti-PEG antibodies that then affect the therapeutic efficacy of subsequent doses of PEGylated therapeutics. (Keyword) Mice / Humans / Animals / Liposomes / Drug Compounding / COVID-19 Vaccines / Immunoglobulin M / Polyethylene Glycols / Neoplasms / Doxorubicin (Link to Publication Site) ● Publication site (DOI): 10.1021/acs.molpharmaceut.3c00774 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38273445 ● CiNii @ National Institute of Informatics (CRID): 1360301163936245376 ● Summary page in Scopus @ Elsevier: 2-s2.0-85184304070 (DOI: 10.1021/acs.molpharmaceut.3c00774, PubMed: 38273445, CiNii: 1360301163936245376, Elsevier: Scopus)
4.	Taro Shimizu, Lila S Abu Amr, Yuka Kitayama, Ryo Abe, Haruka Takata, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : Peritoneal B Cells Play a Role in The Production of Anti-Polyethylene Glycol (PEG) IgM Against Intravenously Injected siRNA-PEGylated Liposome Complexes, Biological & Pharmaceutical Bulletin, Vol.47, No.2, 469-477, 2024. (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b23-00733 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1248/bpb.b23-00733 (DOI: 10.1248/bpb.b23-00733)
5.	Shunsuke Akagi, Hidenori ANDO, Nana Matsuo, Kenji Tajima, Haruka Takata, Tokuo Matsushima, Takatomo Kusano and Tatsuhiro Ishida : A 3D cell-culture system that uses nano-fibrillated bacterial cellulose (NFBC) to prepare a spherical formulation of culture cells, Biological & Pharmaceutical Bulletin, 2024.
6.	横山宏司, 儘田光和, Haruka Takata, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : マクロゴール4000の関連する全身性紅斑を呈した女児例, Pediatrics of Japan, Vol.64, No.11, 1196-1199, 2023. (Link to Publication Site) ● Publication site (DOI): 10.18888/sh.0000002763 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390579686915245568 ● Search Scopus @ Elsevier (DOI): 10.18888/sh.0000002763 (DOI: 10.18888/sh.0000002763, CiNii: 1390579686915245568)
7.	Haruka Takata, Taro Shimizu, Rina Yamade, Nehal Ali Emam Elsadek Emam Elhewan, Sherif Abdallah Emam Emam, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route, Journal of Controlled Release, Vol.360, 285-292, 2023. (Summary) Modifying the surface of nanoparticles with polyethylene glycol (PEG) is a commonly used approach for improving the in vitro stability of nanoparticles such as liposomes and increasing their circulation half-lives. We have demonstrated that, in certain conditions, an intravenous (i.v.) injection of PEGylated liposomes (PEG-Lip) induced anti-PEG IgM antibodies, which led to rapid clearance of second doses in mice. SARS-CoV-2 vaccines, composed of mRNA-containing PEGylated lipid nanoparticles, have been widely administered as intramuscular (i.m.) injections, so it is important to determine if PEGylated formulations can induce anti-PEG antibodies. If the favorable properties that PEGylation imparts to therapeutic nanoparticles are to be widely applicable this should apply to various routes of administration. However, there are few reports on the effect of different administration routes on the in vivo production of anti-PEG IgM. In this study, we investigated anti-PEG IgM production in mice following i.m., intraperitoneal (i.p.) and subcutaneous (s.c.) administration of PEG-Lip. PEG-Lip appeared to induce anti-PEG IgM by all the tested routes of administration, although the lipid dose causing maximum responses varied. Splenectomy attenuated the anti-PEG IgM production for all routes of administration, suggesting that splenic immune cells may have contributed to anti-PEG IgM production. Interestingly, in vitro experiments indicated that not only splenic cells but also cells in the peritoneal cavity induced anti-PEG IgM following incubation with PEG-Lip. These observations confirm previous experiments that have shown that measurable amounts of PEG-Lip administered i.p., i.m. or s.c. are absorbed to some extent into the blood circulation, where they can be distributed to the spleen and/or peritoneal cavity, and are recognized by B cells, triggering anti-PEG IgM production. The results obtained in this study have important implications for developing efficient PEGylated nanoparticular delivery system. (Keyword) Mice / Animals / Humans / Polyethylene Glycols / Liposomes / COVID-19 Vaccines / Immunoglobulin M / COVID-19 / SARS-CoV-2 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jconrel.2023.06.027 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37355210 ● Search Scopus @ Elsevier (PMID): 37355210 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jconrel.2023.06.027 (DOI: 10.1016/j.jconrel.2023.06.027, PubMed: 37355210)
8.	Hidenori ANDO, Kiyoshi Eshima and Tatsuhiro Ishida : A polyethylene glycol-conjugate of deoxycytidine analog, DFP-14927, produces potential antitumor effects on pancreatic tumor-xenograft murine models via inducing G2/M arrest, European Journal of Pharmacology, Vol.950, 175758, 2023. (Summary) A deoxycytidine analog is a potential agent for the treatment of several cancers, which includes poorly prognostic pancreatic cancer. We previously developed deoxycytidine analog DFP-10917, and long-term/low-dose infusions of this analog has produced antitumor effects in leukemia cancer- and ovarian cancer-xenograft models. DFP-10917 is now undergoing clinical Phase III study in the United States for the treatment of patients with relapsed or refractory acute myeloid leukemia. PEG-drug conjugation has become a promising technique to improve the pharmacokinetic and pharmacodynamic properties of anti-cancer drugs. In the present study, we synthesized a novel PEG-drug conjugate of DFP-10917, referred to hereafter as DFP-14927, using a 4-armed CTPEG system to endow the DFP-10917 drug with favorable long-circulating properties that maximize its utility and antitumor efficacy. Intravenous injection of the synthesized DFP-14927 returned encouraging antitumor effects in a Panc-1 human pancreatic tumor- and a BxPC-3 human pancreatic tumor-xenograft models. These effects were comparable to that of free DFP-10917 as well as to that of gemcitabine, which is considered a standard in the treatment of pancreatic cancer. In vitro studies revealed that DFP-14927 inhibits cell division on human pancreatic cancer cell lines via arrest of the G2/M phase in the cell cycle, which is consistent with the effects of free DFP-10917. Intravenous administration of the newly synthesized DFP-14927 has induced G2/M arrest in human pancreatic tumor-xenograft murine models, which represents an improvement in the pharmacokinetics of DFP-10917. DFP-14927 could be an alternative for patients who cannot accept prolonged or continuous infusions of DFP-10917. (Keyword) Female / Humans / Animals / Mice / Disease Models, Animal / Apoptosis / Heterografts / Cell Line, Tumor / G2 Phase Cell Cycle Checkpoints / Deoxycytidine / Pancreatic Neoplasms / Xenograft Model Antitumor Assays (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ejphar.2023.175758 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37121563 ● Search Scopus @ Elsevier (PMID): 37121563 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ejphar.2023.175758 (DOI: 10.1016/j.ejphar.2023.175758, PubMed: 37121563)
9.	Taro Shimizu, Takaaki Matsuzaki, Shoishiro Fukuda, Chihiro Yoshioka, Yuna Shimazaki, Shunsuke Takese, Katsuhiro Yamanaka, Takashi Nakae, Masaki Ishibashi, Hidetoshi Hamamoto, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : Ionic liquid-based transcutaneous peptide antitumor vaccine; therapeutic effect in a mouse tumor model, The AAPS Journal, Vol.25, No.2, 27, 2023. (Summary) Traditional vaccinations need to be injected with needles, and since some people have a strong aversion to needles, a needle-free alternative delivery system is important. In this study, we employed ionic liquids (ILs) for transcutaneous delivery of cancer antigen-derived peptides to obtain anticancer therapeutic effects in a needle-free manner. ILs successfully increased the in vitro skin permeability of a peptide from Wilms tumor 1 (WT1), one of the more promising cancer antigens, plus or minus an adjuvant, resiquimod (R848), a toll-like receptor 7 agonist. In vivo studies demonstrated that concomitant transcutaneous delivery of WT1 peptide and R848 by ILs induced WT1-specific cytotoxic T lymphocyte (CTL) in mice, resulting in tumor growth inhibition in Lewis lung carcinoma-bearing mice. Interestingly, administrating R848 in ILs before WT1 peptides in ILs increased tumor growth inhibition effects compared to co-administration of both. We found that the prior application of R848 increased the infiltration of leukocytes in the skin and that subsequent delivery of WT1 peptides was more likely to induce WT1-specific CTL. Furthermore, sequential immunization with IL-based formulations was applicable to different types of peptides and cancer models without induction of skin irritation. IL-based transcutaneous delivery of cancer antigen-derived peptides and adjuvants, either alone or together, could be a novel approach to needle-free cancer therapeutic vaccines. (Keyword) Animals / Mice / Ionic Liquids / Neoplasms / Vaccines, Subunit / Adjuvants, Immunologic / Cancer Vaccines / Disease Models, Animal (Link to Publication Site) ● Publication site (DOI): 10.1208/s12248-023-00790-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36805860 ● Search Scopus @ Elsevier (PMID): 36805860 ● Search Scopus @ Elsevier (DOI): 10.1208/s12248-023-00790-w (DOI: 10.1208/s12248-023-00790-w, PubMed: 36805860)
10.	Mohamed Ibrahim, Taro Shimizu, Hidenori ANDO, Yu Ishima, Helmy Omar Elgarhy, A Hatem Sarhan, K Amal Hussein and Tatsuhiro Ishida : Investigation of anti-PEG antibody response to PEG-containing cosmetic products in mice, Journal of Controlled Release, Vol.354, 260-267, 2023. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jconrel.2023.01.012 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.jconrel.2023.01.012 (DOI: 10.1016/j.jconrel.2023.01.012)
11.	Naoto Okada, Taro Shimizu, Hidenori ANDO, Shingen Nakamura, Mitsuhiro Goda, Masahiro Abe, Takashi Kitahara, Tatsuhiro Ishida and Keisuke Ishizawa : Clinical impact of anti-polyethylene glycol (PEG) antibody in haematological patients administered PEGylated-granulocyte colony-stimulating factor, Clinical Pharmacology in Drug Development, Vol.12, No.8, 826-831, 2023. (Summary) Polyethylene glycol (PEG) is a polymer covalently attached to proteins to improve their half-life and efficacy. We previously reported that the PEGylated granulocyte colony-stimulating factor (PEG-G-CSF) is immunogenic, which could adversely impact drug efficacy and safety in animal models. Here, we analyzed the relationship between anti-PEG antibody titers and the clinical impact of PEG-G-CSF in 19 hematological patients. A gradual decrease of anti-PEG antibody titers from baseline was observed after PEG-G-CSF administration. Of the 19 participants, 10 were assessed for noninfectious fever after the first administration of PEG-G-CSF and three experienced this reaction. The receiver operating characteristic curve revealed that the cut-off values of pretreated anti-PEG IgM and IgG titers for noninfectious fever were set at 5.0 and 96.6 U/mL, respectively. All patients who experienced noninfectious fever had anti-PEG antibody titers above this cut-off value (P = .033). An enzyme-linked immunosorbent assay revealed that some anti-PEG antibodies in patients with anti-PEG antibody titers above the cut-off value reacted with the PEGylated liposome. These results indicate the reactivity of the anti-PEG antibodies to PEGylated therapeutics observed in hematologic patients and the possibility of the relationship between high titers of anti-PEG antibodies and the development of adverse events after PEG-G-CSF administration. (Link to Publication Site) ● Publication site (DOI): 10.1002/cpdd.1225 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36708147 ● Search Scopus @ Elsevier (PMID): 36708147 ● Search Scopus @ Elsevier (DOI): 10.1002/cpdd.1225 (DOI: 10.1002/cpdd.1225, PubMed: 36708147)
12.	Kohki Tachibana, Kohshi Kusumoto, Mai Ogawa, Hidenori ANDO, Taro Shimizu, Yu Ishima, Tatsuhiro Ishida and Keiichiro Okuhira : FTY720 reduces lipid accumulation by upregulating ABCA1 through liver X receptor and sphingosine kinase 2 signaling in macrophages, International Journal of Molecular Sciences, Vol.23, 14617, 2022. (Tokushima University Institutional Repository) ● Metadata: 118017 (Link to Publication Site) ● Publication site (DOI): 10.3390/ijms232314617 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.3390/ijms232314617 (Tokushima University Institutional Repository: 118017, DOI: 10.3390/ijms232314617)
13.	Yu Ishima, Nio Yamazaki, V Chuang, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : A maleimide-terminally modified PEGylated liposome induced the accelerated blood clearance independent of the production of anti-PEG IgM antibodies, Biological & Pharmaceutical Bulletin, Vol.45, No.10, 1518-1524, 2022. (Keyword) liposome / polyethylene glycol / accelerated blood clearance / maleimide / complement activation (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b22-00389 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390856583390911232 ● Search Scopus @ Elsevier (DOI): 10.1248/bpb.b22-00389 (DOI: 10.1248/bpb.b22-00389, CiNii: 1390856583390911232)
14.	Hidenori ANDO, Ai Ikeda, Maho Tagami, Nana Matsuo, Taro Shimizu, Yu Ishima, K Eshima and Tatsuhiro Ishida : Oral administration of sodium bicarbonate can enhance the therapeutic outcome of Doxil® via neutralizing the acidic tumor microenvironment, Journal of Controlled Release, Vol.350, 414-420, 2022. (Summary) The pH of the tumor microenvironment in solid tumors is reported to be more acidic than that of normal tissues. The pH is controlled by over-expression of several transporters that are associated with the progression, angiogenesis, and metastasis of solid tumors. Antitumor effects of weak-base anticancer agents, such as doxorubicin (DXR), could be reduced in an acidic environment because of increases in the ionized form of the drug under these conditions, reducing its membrane penetrability. In our previous studies, we demonstrated that oral administration of sodium bicarbonate (NaHCO) can neutralize the acidic tumor microenvironment and enhance the effects of small molecule anticancer drugs. However, it is not known whether or not increasing the tumor pH by oral administration of NaHCO leads to enhanced antitumor effects of lipidic nanoparticle formulations of weak-base anticancer drugs, such as Doxil®. In this study, we investigated the antitumor efficacy of Doxil® in combination with oral administration of NaHCO in a Colon26 tumor-bearing mouse model. NaHCO clearly enhanced the tumor-growth inhibitory effect of Doxil® without exacerbating any systemic side effects. In vitro studies indicated that high levels of DXR were internalized into cells at neutral pH. These studies demonstrate that the neutralization of acidic tumor microenvironment by an oral administration of NaHCO could be a promising approach to enhance the therapeutic outcomes of Doxil®. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jconrel.2022.08.031 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35988781 ● Search Scopus @ Elsevier (PMID): 35988781 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jconrel.2022.08.031 (DOI: 10.1016/j.jconrel.2022.08.031, PubMed: 35988781)
15.	Yoshino Kawaguchi, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : Development of a nanocarrier-based splenic B cell-targeting system for loading antigens in vitro, Biological & Pharmaceutical Bulletin, Vol.45, No.7, 926-933, 2022. (Tokushima University Institutional Repository) ● Metadata: 117224 (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b22-00222 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1248/bpb.b22-00222 (Tokushima University Institutional Repository: 117224, DOI: 10.1248/bpb.b22-00222)
16.	Taro Shimizu, Yoshino Kawaguchi, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : Development of an antigen delivery system for a B cell-targeted vaccine as an alternative to dendritic cell-targeted vaccines, Chemical & Pharmaceutical Bulletin, Vol.70, No.5, 341-350, 2022. (Link to Publication Site) ● Publication site (DOI): 10.1248/cpb.c22-00047 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1248/cpb.c22-00047 (DOI: 10.1248/cpb.c22-00047)
17.	Ryota Sumitomo, Cheng-long Huang, Hidenori ANDO, Tatsuhiro Ishida, Hiroyuki Cho and Hiroshi Date : Wnt2b and Wnt5a expressions are highly associated with M2 TAMs in non-small-cell lung cancer, Oncology Reports, Vol.48, No.5, 189, 2022. (Summary) Tumor-associated macrophages (TAMs), particularly M2 macrophages, promote tumor progression, while genes encode a family of multi-functional glycoproteins that serve an important role in tumorigenesis. Immunohistochemical studies were performed to evaluate Wnt2b and Wnt5a expression in tumor and stromal cells in M2 and M1 TAMs and Ki-67 proliferation index in 160 consecutive patients with resected non-small cell lung cancer (NSCLC). Overall, 52 tumors (32.5%) were classified as tumoral Wnt2b-high (Wnt2b-positive tumor cells >30%) and 95 (59.4%) as stromal Wnt2b-high (Wnt2b-positive stromal cells >30%), while 75 (46.9%) were classified as tumoral Wnt5a-high (Wnt5a-positive tumor cells >30%) and 63 (39.4%) as stromal Wnt5a-high (Wnt5a-positive stromal cells >28%). The density of M2 TAMs was significantly higher in the tumoral (P=0.0024) and stromal Wnt2b-high groups (P=0.0054). The density of M2 TAMs was also significantly higher in the tumoral (P=0.0005) and stromal Wnt5a-high groups (P=0.0486). By contrast, no difference in stromal or islet M1 TAM density was observed in relation to tumoral or stromal Wnt2b or Wnt5a status. Furthermore, Ki-67 proliferation index was significantly higher in the tumoral (P=0.0121) and stromal Wnt2b-high (P=0.0019) and tumoral Wnt5a-high (P=0.0088) groups. Overall survival rate was significantly lower in the Wnt2b-high (P=0.0437), Wnt5a-high (P=0.0106) and M2 TAM-high (P=0.0060) groups. Wnt2b and Wnt5a expression in tumor and stromal cells may induce M2 TAMs to produce more aggressive behavior during tumor progression in NSCLC. (Keyword) Carcinoma, Non-Small-Cell Lung / Glycoproteins / Humans / Immunohistochemistry / Ki-67 Antigen / Lung Neoplasms / Tumor-Associated Macrophages / Wnt Proteins / Wnt-5a Protein (Link to Publication Site) ● Publication site (DOI): 10.2139/ssrn.4088768 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36102318 ● Search Scopus @ Elsevier (PMID): 36102318 ● Search Scopus @ Elsevier (DOI): 10.2139/ssrn.4088768 (DOI: 10.2139/ssrn.4088768, PubMed: 36102318)
18.	Marwa Sayed El, Taro Shimizu, Lila Selim Ahmed Ali Abu Amr, Elhewan Emam Elsadek Emam Ali Nehal, Emam Emam Abdallah Sherif, Eman Alaaeldin, Amal Kamal, Hatem Sarhan, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : A mouse model for studying the effect of blood anti-PEG IgMs levels on the in vivo fate of PEGylated liposomes, International Journal of Pharmaceutics, Vol.615, 121539, 2022. (Summary) The presence of anti-polyethylene glycol (PEG) antibodies in the systemic circulation might have potential implications for the therapeutic activity of PEGylated products in vivo in the clinic. In order to study the effect of pre-existing anti-PEG antibodies on the in vivo fate and the therapeutic efficiency of PEGylated therapeutics, we developed a BALB/c mouse model by virtue of the intraperitoneal (i.p.) inoculation of hybridoma cells (HIK-M09 and HIK-M11), secreting monoclonal anti-PEG IgM, mimicking the presence of pre-existing anti-PEG antibodies in the blood. In the model, the titers of anti-PEG IgM in the blood increased as a function of hybridoma cells numbers and time after i.p. inoculation. The in vivo levels of anti-PEG IgM decreased in a dose-dependent manner, following i.v. administration of empty PEGylated liposomes. C26 tumor-bearing mice with measurable levels of anti-PEG IgM, receiving i.v. injection of DiR-labeled empty PEGylated liposomes, showed lower levels of liposomal tumor accumulation and higher levels of liver and spleen accumulation, compared to C26 tumor-bearing mice without measurable anti-PEG IgM. This specifies that the presence of anti-PEG IgM in the murine circulation induced accelerated blood clearance of PEGylated liposomes and reduced their tumor accumulation. The biodistribution and antitumor efficacy of commercially available doxorubicin (DXR)-containing PEGylated liposomes, Doxil®, were scrutinized in the anti-PEG IgM mouse model. In C26 tumor-bearing mice having circulating anti-PEG IgM, at 24 h after injection almost no DXR was observed in blood and tumor, and increased DXR accumulation was observed in spleen and liver, compared to tumor-bearing mice with no circulating anti-PEG IgM. The antitumor efficacy of Doxil® was significantly compromised in the C26 tumor-bearing mice in the presence of anti-PEG IgM. These results demonstrate that the anti-PEG IgM mouse model could be a useful prognostic indicator for the therapeutic effectiveness of different formulations of PEGylated therapeutics in pre-clinical studies. (Keyword) Animals / Immunoglobulin M / Liposomes / Mice / Mice, Inbred BALB C / Polyethylene Glycols / Tissue Distribution (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijpharm.2022.121539 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35124114 ● Search Scopus @ Elsevier (PMID): 35124114 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ijpharm.2022.121539 (DOI: 10.1016/j.ijpharm.2022.121539, PubMed: 35124114)
19.	M Mostafa Mahmoud, Elhewan Emam Elsadek Emam Ali Nehal, Emam Emam Abdallah Sherif, Hidenori ANDO, Taro Shimizu, H Abdelkader, Yu Ishima, U Aly Farghaly, A H Sarhan and Tatsuhiro Ishida : Using Bio-Layer Interferometry to evaluate anti-PEG antibody-mediated complement activation, Biological & Pharmaceutical Bulletin, Vol.45, No.1, 129-135, 2022. (Summary) The purpose of this study was to develop a Bio-layer interferometry (BLI) system that could be an alternative approach for the direct evaluation of anti-polyethylene glycol (PEG) immunoglobulin M (IgM)-mediated complement activation of the accelerated blood clearance (ABC) phenomenon. Complement activation is well known to play an important role in the clearance of PEGylated and non-PEGylated nanomedicines following intravenous injection. This complement system is also thought to be responsible for the ABC phenomenon wherein repeated injections of PEGylated products are bound by anti-PEG antibodies. This study used three different sources of anti-PEG antibodies: HIK-M09 monoclonal antibodies (mAbs); HIK-M11 mAbs; and antiserum containing polyclonal anti-PEG IgMs. 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-n-[methoxy (polyethylene glycol)-2000] (mPEG-DSPE) was immobilized as an antigen on aminopropyl silane biosensor chips of BLI. All anti-PEG IgMs in the sources increased the signals (thickness of the layer around the sensor tip) regarding binding of anti-PEG antibodies to PEG on the chips. In all anti-PEG IgM sources, further increases in the signals were observed when incubated in naïve mouse serum, which is a complement source, but not in heat inactivated (56 °C, 30 min) mouse serum, which abolishes complement activity. These findings show that the complement activation mediated via anti-PEG IgMs, which occurred on the sensor chips, was detected via BLI analysis. The complement activation induced by all anti-PEG IgM sources was confirmed via conventional enzyme-linked immunosorbent assay (ELISA), which is the conventional mode for detection of complement activation. Our study results show that BLI is a simple alternative method for the detection of complement activation. (Keyword) Animals / Complement Activation / Immunoglobulin M / Interferometry / Liposomes / Mice / Polyethylene Glycols (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b21-00772 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34980774 ● CiNii @ National Institute of Informatics (CRID): 1390290617368317184 ● Summary page in Scopus @ Elsevier: 2-s2.0-85123166599 (DOI: 10.1248/bpb.b21-00772, PubMed: 34980774, CiNii: 1390290617368317184, Elsevier: Scopus)
20.	Rie Ando-Matsuoka, Hidenori ANDO, Lila Selim Ahmed Ali Abu Amr, Noriyuki Maeda, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : I.p.-injected cationic liposomes are retained and accumulate in peritoneally disseminated tumors, Journal of Controlled Release, Vol.341, 524-532, 2022. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jconrel.2021.12.004 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.jconrel.2021.12.004 (DOI: 10.1016/j.jconrel.2021.12.004)
21.	Keisuke Mogi, Ikumi Kamiya, Aimi Makino, Ayaka Hirao, Reina Abe, Yusuke Doi, Taro Shimizu, Hidenori ANDO, Katsuya Morito, Kentaro Takayama, Tatsuhiro Ishida and Kazuki Nagasawa : Liposomalization of oxaliplatin exacerbates the non-liposomal formulation-induced decrease of sweet taste sensitivity in rats, Journal of Pharmaceutical Sciences, Vol.110, No.12, 3937-3945, 2021. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.xphs.2021.07.004 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.xphs.2021.07.004 (DOI: 10.1016/j.xphs.2021.07.004)
22.	Eisaku Ohashi, Sangita Karanjit, Atsushi Nakayama, Kohei Takeuchi, Sherif E Emam, Hidenori ANDO, Tatsuhiro Ishida and Kosuke Namba : Efficient construction of the hexacyclic ring core of palau'amine: the pK_a concept for proceeding with unfavorable equilibrium reactions, Chemical Science, Vol.12, 2021. (Tokushima University Institutional Repository) ● Metadata: 116279 (Link to Publication Site) ● Publication site (DOI): 10.1039/D1SC03260G (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1039/D1SC03260G (Tokushima University Institutional Repository: 116279, DOI: 10.1039/D1SC03260G)
23.	Ryo Kinoshita, Yu Ishima, Victor T.G. Chuang, Hiroshi Watanabe, Taro Shimizu, Hidenori ANDO, Keiichiro Okuhira, Masaki Otagiri, Tatsuhiro Ishida and Toru Maruyama : The therapeutic effect of HSA dimer-doxorubicin complex against human pancreatic tumour, Pharmaceutics, Vol.13, No.8, 1209, 2021. (Tokushima University Institutional Repository) ● Metadata: 116618 (Link to Publication Site) ● Publication site (DOI): 10.3390/pharmaceutics13081209 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.3390/pharmaceutics13081209 (Tokushima University Institutional Repository: 116618, DOI: 10.3390/pharmaceutics13081209)
24.	Hidenori ANDO, Takashi Mochizuki, Amr Abu Ali Ahmed Selim Lila, Shunsuke Akagi, Kenji Tajima, Kenji Fujita, Taro Shimizu, Yu Ishima, Tokuo Matsushima, Takatomo Kusano and Tatsuhiro Ishida : Doxorubicin embedded into nanofibrillated bacterial cellulose (NFBC) produces a promising therapeutic outcome for peritoneally metastatic gastric cancer in mice models via intraperitoneal direct injection, Nanomaterials, Vol.11, 1697, 2021. (Tokushima University Institutional Repository) ● Metadata: 116603 (Link to Publication Site) ● Publication site (DOI): 10.3390/nano11071697 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.3390/nano11071697 (Tokushima University Institutional Repository: 116603, DOI: 10.3390/nano11071697)
25.	Emam Emam Abdallah Sherif, Elhewan Emam Elsadek Emam Ali Nehal, Lila Selim Ahmed Ali Abu Amr, Haruka Takata, Yoshino Kawaguchi, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : Anti-PEG IgM production and accelerated blood clearance phenomenon after the administration of PEGylated exosomes in mice, Journal of Controlled Release, Vol.334, 327-334, 2021. (Summary) Recently, there is an increasing interest in exosomes or extracellular vesicles as potential candidates for delivering RNAs, proteins, genes, and anticancer agents. Engineering of exosome properties is rapidly evolving as a means of expanding exosome applications. PEGylation of exosomes is a technique used to improve their in vivo stability, circulation half-lives, and sometimes to allow the binding targeting ligands to the exosome exterior. According to FDA guidelines for the development of PEGylated proteins, immunological responses to PEGylated molecules and particles should be examined. In this study, we prepared PEGylated exosomes and investigated the production of anti-PEG IgM antibodies after single i.v. injections in mice. In addition, we monitored blood concentrations and tumor accumulation of a second dose of PEGylated exosomes administered after the initial dose. Single injections of PEGylated exosomes in mice induced anti-PEG IgM production in a T cell-dependent manner. The anti-PEG IgM production decreased when the injection dose of PEGylated exosomes was further increased. Anti-PEG IgM induced by injection of PEGylated exosomes decreased blood concentrations of a second dose of PEGylated exosomes and suppressed their tumor accumulation in a C26 murine colorectal cancer model. Initial injection doses of either PEGylated liposomes or PEGylated ovalbumin (PEG-OVA), both of them induced anti-PEG IgM production, also decreased the blood concentration of PEGylated exosomes. Interestingly, anti-PEG IgM induced by injection of PEGylated exosomes did not affect the blood concentration of PEG-OVA. These results imply the importance of monitoring anti-PEG IgM when repeat PEGylated exosome doses are required and/or when PEGylated exosomes are used together with other PEGylated therapeutics. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jconrel.2021.05.001 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33957196 ● Summary page in Scopus @ Elsevier: 2-s2.0-85105280797 (DOI: 10.1016/j.jconrel.2021.05.001, PubMed: 33957196, Elsevier: Scopus)
26.	Milad Reda Qelliny, Taro Shimizu, Nehal Ali Emam Elsadek Emam Elhewan, Sherif Abdallah Emam Emam, Haruka Takata, Zeinab M. A. Fathalla, Amal K. Hussein, Khaled A. Khaled, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : Incorporating gangliosides into PEGylated cationic liposomes that complexed DNA attenuates anti-PEG antibody production, but not anti-DNA antibody production in mice, Molecular Pharmaceutics, Vol.18, No.6, 2406-2415, 2021. (Summary) Gangliosides (glycosphingolipids) reduce antibody production by inhibiting B-cell receptor (BCR) signaling. We have shown that a copresentation of gangliosides and polyethylene glycol (PEG) on the same liposomes suppresses anti-PEG IgM production in mice. In addition, we recently observed that pDNA incorporated in PEGylated cationic liposomes (PCLs) induces anti-DNA IgM, which could be a hurdle to the development of efficient gene delivery systems. Therefore, the focus of this study was to determine if the copresentation of gangliosides and DNA on the same PCL would suppress antibody production against DNA. PCLs including DNA induced both anti-PEG IgM production and anti-DNA IgM production. The extent of anti-PEG and anti-DNA IgM production was likely dependent on the immunogenicity of the complexed DNA. Treatment of clodronate-containing liposomes, which causes a depletion of phagocytic cells, suppressed anti-PEG IgM production from PCLs that did not include DNA but failed to suppress anti-PEG IgM production from PCLs that complexed DNA (PCLD). Both anti-PEG IgM and anti-DNA IgM was induced in T-cell-deficient nude mice as well as in normal mice following treatment with PCLs and PCLD, respectively. These results indicate that phagocytic cells contribute to anti-PEG IgM production but not to anti-DNA IgM production, while T-cells do not contribute to any form of antibody production. The copresentation of gangliosides and DNA significantly reduced anti-PEG IgM production but unfortunately did not reduce anti-DNA IgM production. It appears that the immunosuppressive effect of gangliosides, presumably via the CD22 signaling pathway, is limited only to anti-PEG immunity. (Keyword) Animals / Antibody Formation / Cations / Clodronic Acid / DNA / Gangliosides / Gene Transfer Techniques / Genetic Therapy / Immunoglobulin M / Liposomes / Male / Mice / Phagocytes / Plasmids / Polyethylene Glycols (Link to Publication Site) ● Publication site (DOI): 10.1021/acs.molpharmaceut.1c00255 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33896187 ● Search Scopus @ Elsevier (PMID): 33896187 ● Search Scopus @ Elsevier (DOI): 10.1021/acs.molpharmaceut.1c00255 (DOI: 10.1021/acs.molpharmaceut.1c00255, PubMed: 33896187)
27.	Hidenori ANDO, Yuta Murakami, Kiyoshi Eshima and Tatsuhiro Ishida : A novel polyethylene glycol (PEG)-drug conjugate of Venetoclax, a Bcl-2 inhibitor, for treatment of acute myeloid leukemia (AML), Cancer Reports, Vol.5, No.3, e1485, 2021. (Summary) Venetoclax (VTX) is an anticancer drug. It is a selective Bcl-2 inhibitor that is clinically used for the treatment of patients with lymphomas and leukemias. Treatment with VTX, however, is accompanied by severe adverse events such as tumor lysis syndrome and neutropenia, because VTX readily binds to serum proteins, which results in poor pharmacokinetics and poor tumor tissue concentration. To avoid such adverse events, VTX is administered using a daily or weekly ramp-up schedule that is cumbersome in clinical situations. To overcome these shortcomings, we prepared a novel polyethylene glycol (PEG)-drug conjugate of VTX (PEG-VTX) and evaluated its cytotoxic effects on acute myeloid leukemia (AML) both in vitro and in vivo. VTX and 4-armed PEG derivatives were covalently attached through an amide bond linker. In a series of in vitro studies, PEG-VTX selectively induced potent growth inhibition of MV4-11 human AML cells via the inducement of Bcl-2-mediated apoptosis. PEG-VTX had the effect of free VTX, presumably due to the protease-mediated release of VTX from the conjugates. In in vivo studies with AML tumor-xenograft mice models, intravenous PEG-VTX promoted sufficient tumor growth suppression. Compared with a regimen of oral free VTX, the intravenous regimen in those studies used a VTX dosage that was 15-30 times smaller for an OCI-AML-2 xenograft model and a dosing regimen that was less frequent for an MV4-11 xenograft model. The most important development, however, was the absence of weight loss related to severe side effects throughout the treatments. An increase in water solubility and the resultant hydrodynamic size of VTX via PEGylation improved the pharmacokinetics of VTX by avoiding protein interactions and lessening the extravasation from blood. The result was an increase in tumor accumulation and a decrease in the nonspecific distribution of VTX. The results of this study suggest that PEG-VTX could be an alternative therapeutic option for the safe and effective treatment of patients with AML. (Keyword) Animals / Antineoplastic Agents / Bridged Bicyclo Compounds, Heterocyclic / Humans / Leukemia, Myeloid, Acute / Mice / Polyethylene Glycols / Sulfonamides (Tokushima University Institutional Repository) ● Metadata: 116506 (Link to Publication Site) ● Publication site (DOI): 10.1002/cnr2.1485 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34173723 ● Search Scopus @ Elsevier (PMID): 34173723 ● Search Scopus @ Elsevier (DOI): 10.1002/cnr2.1485 (Tokushima University Institutional Repository: 116506, DOI: 10.1002/cnr2.1485, PubMed: 34173723)
28.	Hidenori ANDO, Sherif Abdallah Emam Emam, Yoshino Kawaguchi, Taro Shimizu, Yu Ishima, Kiyoshi Eshima and Tatsuhiro Ishida : Increasing tumor extracellular pH by an oral alkalinizing agent improves antitumor responses of anti-PD-1 antibody: Implication of relationships between serum bicarbonate concentrations, urinary pH, and therapeutic outcomes, Biological & Pharmaceutical Bulletin, Vol.44, No.6, 844-852, 2021. (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b21-00076 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1248/bpb.b21-00076 (DOI: 10.1248/bpb.b21-00076)
29.	Naoki Hirakawa, Yu Ishima, Ryo Kinoshita, Ryuto Nakano, Chuang Tuan Giam Victor, Hidenori ANDO, Taro Shimizu, Keiichiro Okuhira, Toru Maruyama, Masaki Otagiri and Tatsuhiro Ishida : Reduction-responsive and Multi-drug Deliverable Albumin Nanoparticles: an antitumor drug to Abraxane® against Human Pancreatic Tumor-Bearing Mice, ACS Applied Bio Materials, Vol.4, No.5, 4302-4309, 2021. (Link to Publication Site) ● Publication site (DOI): 10.1021/acsabm.1c00110 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1021/acsabm.1c00110 (DOI: 10.1021/acsabm.1c00110)
30.	Haruka Takata, Taro Shimizu, Yoshino Kawaguchi, Hiro Ueda, Nehal Ali Emam Elsadek Emam Elhewan, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : Nucleic acids delivered by PEGylated cationic liposomes in systemic lupus erythematosus-prone mice: a possible exacerbation of lupus nephritis in the presence of pre-existing anti-nucleic acid antibodies, International Journal of Pharmaceutics, Vol.601, 120529, 2021. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijpharm.2021.120529 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.ijpharm.2021.120529 (DOI: 10.1016/j.ijpharm.2021.120529)
31.	Maichi Hama, Yu Ishima, Chuang V, Hidenori ANDO, Taro Shimizu and Tatsuhiro Ishida : Evidence for delivery of Abraxane® via a denatured-albumin transport system, ACS Applied Materials & Interfaces, Vol.13, No.17, 19736-19744, 2021. (Link to Publication Site) ● Publication site (DOI): 10.1021/acsami.1c03065 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1021/acsami.1c03065 (DOI: 10.1021/acsami.1c03065)
32.	Shunsuke Akagi, Hidenori ANDO, Kenji Fujita, Taro Shimizu, Yu Ishima, Kenji Tajima, Tokuo Matsushima, Takatomo Kusano and Tatsuhiro Ishida : Therapeutic efficacy of a paclitaxel-loaded nanofibrillated bacterial cellulose (PTX/NFBC) formulation in a peritoneally disseminated gastric cancer xenograft model, International Journal of Biological Macromolecules, Vol.174, 494-501, 2021. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijbiomac.2021.01.201 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.ijbiomac.2021.01.201 (DOI: 10.1016/j.ijbiomac.2021.01.201)
33.	Taro Shimizu, Yuki Watanabe, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : Lymphoid follicle antigen (Ag) delivery and enhanced rodent humoral immune responses mediated by Ag-containing PEGylated liposomes, Vaccine, Vol.39, No.7, 1131-1139, 2021. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.vaccine.2021.01.008 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.vaccine.2021.01.008 (DOI: 10.1016/j.vaccine.2021.01.008)
34.	Hidenori ANDO, Kiyoshi Eshima and Tatsuhiro Ishida : Neutralization of acidic tumor microenvironment (TME) with daily oral dosing of sodium potassium citrate (K/Na Citrate) increases therapeutic effect of anti-cancer agent in pancreatic cancer xenograft mice model, Biological & Pharmaceutical Bulletin, Vol.44, No.2, 266-270, 2021. (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b20-00825 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1248/bpb.b20-00825 (DOI: 10.1248/bpb.b20-00825)
35.	Taro Shimizu, Mizuki Awata, Lila Selim Ahmed Ali Abu Amr, Chihiro Yoshioka, Yoshino Kawaguchi, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : Complement activation induced by PEG enhances humoral immune responses against antigens encapsulated in PEG-modified liposomes, Journal of Controlled Release, Vol.329, 1046-1053, 2021. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jconrel.2020.10.033 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.jconrel.2020.10.033 (DOI: 10.1016/j.jconrel.2020.10.033)
36.	Takuma Takayama, Taro Shimizu, Lila Selim Ahmed Ali Abu Amr, Yuki Kanazawa, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : Adjuvant antitumor immunity contributes to the overall antitumor effect of PEGylated liposomal doxorubicin (Doxil®) in C26 tumor-bearing immunocompetent mice, Pharmaceutics, Vol.12, No.10, 990, 2020. (Tokushima University Institutional Repository) ● Metadata: 116247 (Link to Publication Site) ● Publication site (DOI): 10.3390/pharmaceutics12100990 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.3390/pharmaceutics12100990 (Tokushima University Institutional Repository: 116247, DOI: 10.3390/pharmaceutics12100990)
37.	Shota Fuimoto, Naoki Muguruma, Michiyasu Nakao, Hidenori ANDO, Takanori Kashihara, Yoshihiko Miyamoto, Koichi Okamoto, Shigeki Sano, Tatsuhiro Ishida, Yasushi Sato and Tetsuji Takayama : Indocyanine green-labeled dasatinib as a new fluorescent probe for molecular imaging of gastrointestinal stromal tumors., Journal of Gastroenterology and Hepatology, Vol.36, No.5, 1253-1262, 2020. (Summary) It is difficult to differentiate gastrointestinal stromal tumors (GISTs) from other subepithelial lesions under gastrointestinal endoscopy. Because most GISTs express tyrosine kinase receptor c-KIT, fluorescence-labeled c-KIT-specific tyrosine kinase inhibitors seem to be useful agents for molecular imaging of GIST. We aimed to develop a near-infrared fluorescent imaging technology for GIST targeting c-KIT using the novel fluorescent probe indocyanine green-labeled dasatinib (ICG-dasatinib) and to investigate the antitumor effect of ICG-dasatinib on GIST cells. Indocyanine green-labeled dasatinib was synthesized by labeling linker-induced dasatinib with ICG derivative 3-indocyanine-green-acyl-1,3-thiazolidine-2-thione. Human GIST cell lines GIST-T1 and GIST-882M were incubated with ICG-dasatinib and observed by fluorescent microscopy. GIST cells were incubated with ICG-dasatinib, unlabeled dasatinib, or imatinib, and cell viabilities were evaluated. Subcutaneous GIST model mice or orthotopic GIST model rats were intravenously injected with ICG-dasatinib and observed using an IVIS Spectrum. Strong fluorescent signals of ICG-dasatinib were observed in both GIST cell lines in vitro. IC50 values for ICG-dasatinib, unlabeled dasatinib, and imatinib were 13.9, 1.17, and 16.2 nM in GIST-T1 and 26.6, 3.63, and 47.6 nM in GIST-882M cells, respectively. ICG-dasatinib accumulated in subcutaneous xenografts in mice. Fluorescent signals were also observed in liver and gallbladder, indicating biliary excretion; however, fluorescence intensity of tumors was significantly higher than that of intestine after washing. Strong fluorescent signals were observed in orthotopic xenografts through the covering normal mucosa in rats. Indocyanine green-labeled dasatinib could visualize GIST cells and xenografted tumors. The antitumor effect of ICG-dasatinib was preserved to the same degree as imatinib. (Link to Publication Site) ● Publication site (DOI): 10.1111/jgh.15281 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32989784 ● Search Scopus @ Elsevier (PMID): 32989784 ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.15281 (DOI: 10.1111/jgh.15281, PubMed: 32989784)
38.	Elhewan Emam Elsadek Emam Ali Nehal, Emam Emam Abdallah Sherif, Lila Selim Ahmed Ali Abu Amr, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : Pegfilgrastim (PEG-G-CSF) induces anti-polyethylene glycol (PEG) IgM via a T cell-dependent mechanism, Biological & Pharmaceutical Bulletin, Vol.43, No.9, 1393-1397, 2020. (Summary) Protein-based therapeutics are beginning to be widely used in various clinical settings. Conjugation of polyethylene glycol (PEGylation) to protein therapeutics improves their circulation half-lives in the body. However, we and other groups observed that the initial dose of some PEGylated protein-based therapeutics may induce anti-PEG antibodies (primarily immunoglobulin M (IgM)), resulting in the accelerated clearance of a second dose. The mechanism behind the induction of anti-PEG IgM by PEGylated protein-based therapeutics is still unclear. In this study, we found that Pegfilgrastim (PEG-G-CSF, the PEGylated form of the recombinant human granulocyte colony-stimulating factor) induced anti-PEG IgM in mice when administered via either intravenous or subcutaneous administration. However, the anti-PEG IgM induction is diminished both in athymic nude mice lacking T cells and in splenectomized mice. In addition, anti-PEG IgM production was significantly diminished in the cyclophosphamide-treated mice depleted of B-cells. These results indicate that anti-PEG IgM production by Pegfilgrastim occurs in spleen in a T cell-dependent manner, which differs from anti-PEG IgM induced by PEGylated liposomes. However, B cells, both marginal zone and follicular, are essential for anti-PEG IgM production in both PEGylated preparations. (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b20-00345 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32879214 ● Search Scopus @ Elsevier (PMID): 32879214 ● Search Scopus @ Elsevier (DOI): 10.1248/bpb.b20-00345 (DOI: 10.1248/bpb.b20-00345, PubMed: 32879214)
39.	A Nguyen, Hidenori ANDO, R Böttger, K K Viswanadham, E Rouhollahi, Tatsuhiro Ishida and S Li : Utilization of Click Chemistry to Study the Effect of Poly(ethylene) Glycol Molecular Weight on the Self-Assembly of PEGylated Gambogic Acid Nanoparticles for the Treatment of Rheumatoid Arthritis, Biomaterials Science, Vol.8, No.16, 4626-4637, 2020. (Summary) Many small-molecule drugs exhibit poor aqueous solubility, and various approaches have been developed to improve their solubility and delivery. Chemical conjugation of an insoluble drug to a hydrophilic polymer can promote the self-assembly into nanoparticles (NPs) to increase the apparent solubility and improve the pharmacokinetics of the drug. However, majority of the reports in the field disclose only one composition of the conjugate, while accumulating evidence suggests that structure-activity relationship (SAR) studies must be conducted to identify an optimal construct. In this study, we employed a click chemistry platform to robustly conjugate short-chain methoxypolyethylene glycol (mPEG) of three different molecular weights to a small molecule anti-inflammatory drug, gambogic acid (GA), and studied the SAR. NPs formed with mPEG550 and mPEG5000, referred to as NP-550 and NP-5000, respectively, had larger mean diameters (130.0 ± 16.9 nm and 143.0 ± 0.1 nm, respectively) and higher critical micellar concentrations (CMCs, 9.5 μg mL-1 and 10.5 μg mL-1, respectively) compared to NPs formed with mPEG2000 (NP-2000, mean diameter = 97.8 ± 5.0 nm and CMC = 6.6 μg mL-1). NP-2000 and NP-5000 did not cause significant hemolytic toxicity, whereas NP-550 and free GA induced 90% and 60% hemolysis, respectively. NP-2000 was selected for further studies due to its improved safety, small size and low CMC. In cultured inflammatory macrophages, NP-2000 exhibited activity comparable to free GA in suppressing tumor necrosis factor-α. In mice, NP-2000 showed 185-fold improved drug exposure compared to free GA after intraperitoneal delivery. Treatment with free GA showed little anti-inflammatory activity compared to vehicle control in a murine model of rheumatoid arthritis. In contrast, NP-2000 significantly reduced the paw inflammation by 27% from day 15 to day 29. NP-2000 showed no visible signs of toxicity in mice, while free GA elicited significant irritation at the injection site. Our work emphasizes the importance of performing SAR studies for developing an optimal drug-polymer conjugate for self-assembly into NPs. We also demonstrate a unique application of click chemistry to robustly synthesize a small library of conjugates for the SAR study. (Link to Publication Site) ● Publication site (DOI): 10.1039/d0bm00711k (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32700691 ● Search Scopus @ Elsevier (PMID): 32700691 ● Search Scopus @ Elsevier (DOI): 10.1039/d0bm00711k (DOI: 10.1039/d0bm00711k, PubMed: 32700691)
40.	Elhewan Emam Elsadek Emam Ali Nehal, Eri Hondoh, Taro Shimizu, Haruka Takata, Lila Selim Ahmed Ali Abu Amr, Emam Emam Abdallah Sherif, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : Impact of pre-existing or induced anti-PEG IgM on the pharmacokinetics of peginterferon alfa-2a (Pegasys®) in mice, Molecular Pharmaceutics, Vol.17, No.8, 2964-2970, 2020. (Summary) PEGylation had been used successfully to improve the circulation half-lives and some physicochemical properties of protein therapeutics. However, anti-polyethylene glycol (anti-PEG) antibodies, either pre-existing or treatment-induced, can negatively affect the pharmacokinetics and pharmacological efficacy of PEGylated proteins. We have examined anti-PEG immune responses in mice for peginterferon alfa-2a (Pegasys), a clinically approved PEGylated protein therapeutic, at both the recommended dose (equivalent to 3 μg/kg in mice) and at higher doses (150 μg/kg) for single or repeated subcutaneous (s.c.) administrations. The effect of treatment-induced anti-PEG IgM on serum concentrations of Pegasys, following repeated administrations, was evaluated. In addition, the effect of pre-existing anti-PEG IgM elicited by a different PEGylated protein, PEG-OVA, on the systemic clearance of Pegasys, was investigated. At a s.c. dose of 3 μg/kg, single injections of Pegasys barely elicited anti-PEG immune responses. Four repeated doses of 150 μg/kg Pegasys elicited anti-PEG IgM production, depending on dose frequency, and triggered the rapid clearance of subsequent doses. In addition, anti-PEG-IgM produced in response to prior administration of PEG-OVA caused a rapid blood clearance of Pegasys. Our results, therefore, underscore the importance of screening for both pre-existing and treatment-induced anti-PEG antibodies in patients prior to and during treatment with PEGylated protein drugs. (Link to Publication Site) ● Publication site (DOI): 10.1021/acs.molpharmaceut.0c00366 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32519877 ● Search Scopus @ Elsevier (PMID): 32519877 ● Search Scopus @ Elsevier (DOI): 10.1021/acs.molpharmaceut.0c00366 (DOI: 10.1021/acs.molpharmaceut.0c00366, PubMed: 32519877)
41.	M Sayed M El, Haruka Takata, Taro Shimizu, Yoshino Kawaguchi, Lila Selim Ahmed Ali Abu Amr, Elhewan Emam Elsadek Emam Ali Nehal, E Alaaeldin, Yu Ishima, Hidenori ANDO, A Kamal, A H Sarhan and Tatsuhiro Ishida : Hepatosplenic phagocytic cells indirectly contribute to anti-PEG IgM production in the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes: Appearance of an unexplained mechanism in the ABC phenomenon, Journal of Controlled Release, Vol.323, 102-109, 2020. (Summary) The accelerated blood clearance (ABC) phenomenon, caused in large degree via in vivo anti-PEG IgM production, is one of obstacles for development of PEGylated liposome and protein formulations, due to decreased efficiency and/or side effects such as anaphylaxis upon repeat administrations. We have shown in murine ABC models that splenectomy suppressed the level of anti-PEG IgM production induced by PEGylated liposomes, indicating that murine splenic B cells play an important role in its production. However, splenectomy did not completely inhibit production of anti-PEG IgM, suggesting that other cells may contribute to its production in the ABC phenomenon. In this study, we examined the contribution of hepatosplenic phagocytic cells to anti-PEG IgM production and clearance of PEGylated liposomes during the ABC phenomenon. Depletion of hepatosplenic phagocytic cells by pretreatment of mice with clodronate-containing non-PEGylated liposomes suppressed anti-PEG IgM production to a considerable degree, without a change in the number of splenic B cells, and attenuated the enhanced clearance of second dose of PEGylated liposomes. These results suggest that hepatosplenic phagocytic cells, in addition to splenic B cells, contribute to the production of anti-PEG IgM and the ABC phenomenon against PEGylated liposomes. The mechanism whereby splenic B cells interact with hepatosplenic phagocytic cells to produce anti-PEG IgM, upon administration of an initial dose of PEGylated liposomes remains to be elucidated. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jconrel.2020.04.011 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32278827 ● Summary page in Scopus @ Elsevier: 2-s2.0-85083399688 (DOI: 10.1016/j.jconrel.2020.04.011, PubMed: 32278827, Elsevier: Scopus)
42.	Nehal Ali Emam Elsadek Emam Elhewan, Amr Abu Ali Ahmed Selim Lila, Sherif Abdallah Emam Emam, Taro Shimizu, Haruka Takata, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administration in mice, European Journal of Pharmaceutics and Biopharmaceutics, Vol.152, 56-62, 2020. (Summary) Pegfilgrastimis a recombinant PEGylated human granulocyte colony-stimulating factor (G-CSF) analog filgrastim (trade names Neulasta® or G-Lasta®) that stimulates the production of white blood cells (neutrophils). It is employed as an alternative to filgrastim (G-CSF) for chemotherapy-induced neutropenia in patients due to its longer half-life. In clinical settings, PEG-G-CSF is administered to cancer patients via both the s.c. and i.v. routes. In a murine study, we showed that, regardless of administration route, initial doses of PEG-G-CSF above 0.06 mg/kg elicited anti-PEG immune response in a dose-dependent manner. I.v. administration elicited higher levels of anti-PEG IgM than the s.c. route. Initial doses of PEG-G-CSF (6 mg/kg) that were high enough to trigger production of anti-PEG IgM, did not trigger the accelerated clearance of a lower subsequent dose (0.06 mg/kg) that was similar to i.v. clinical doses of PEG-G-CSF, but when the subsequent dose of PEG-G-CSF was raised to (6 mg/kg), the initial dose triggered the accelerated clearance of the second dose via an anti-PEG IgM-mediated complement activation. Similar observations were noted when an increased PEG-OVA dose was given as the second dose, indicating that pre-existing and/or treatment-induced anti-PEG antibodies might compromise the therapeutic activity and/or reduce tolerance of other PEGylated formulations. To the best of our knowledge, this is the first report to suggest the induction of the ABC phenomenon upon repeated injections of pegfilgrastim. In the clinic, cancer patients, receiving multiple cycles of chemotherapy, receive multiple cycles of pegfilgrastim to avoid infections and substantial morbidity. The ABC phenomenon to pegfilgrastim appears to be the cause of loss of clinical benefit of sequential treatments with pegfilgrastim in patients. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ejpb.2020.04.026 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32376372 ● Search Scopus @ Elsevier (PMID): 32376372 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ejpb.2020.04.026 (DOI: 10.1016/j.ejpb.2020.04.026, PubMed: 32376372)
43.	Hidenori ANDO, Noriko Saito-Tarashima, Lila Selim Ahmed Ali Abu Amr, Nozomi Kinjoh, Taro Shimizu, Yu Ishima, Noriaki Minakawa and Tatsuhiro Ishida : A unique gene-silencing approach, using an intelligent RNA expression device (iRed), results in minimal immune stimulation when given by local intrapleural injection in malignant pleural mesothelioma, Molecules, Vol.25, No.7, 1725, 2020. (Summary) We have recently introduced an intelligent RNA expression device (iRed), comprising the minimum essential components needed to transcribe short hairpin RNA (shRNA) in cells. Use of iRed efficiently produced shRNA molecules after transfection into cells and alleviated the innate immune stimulation following intravenous injection. To study the usefulness of iRed for local injection, the engineered iRed encoding luciferase shRNA (Luc iRed), complexed with cationic liposomes (Luc iRed/liposome-complexes), was intrapleurally injected into an orthotopic mesothelioma mouse model. Luc iRed/liposome-complexes markedly suppressed the expression of a luciferase marker gene in pleurally disseminated mesothelioma cells. The suppressive efficiency was correlated with the expression level of shRNA within the mesothelioma cells. In addition, intrapleural injection of iRed/liposome-complexes did not induce IL-6 production in the pleural space and consequently in the blood compartment, although plasmid DNA (pDNA) or dsDNA (the natural construct for iRed) in the formulation did. Local delivery of iRed could augment the in vivo gene silencing effect without eliciting pronounced innate immune stimulation. Our results might hold promise for widespread utilization of iRed as an RNAi-based therapeutic for intracelial malignant cancers. (Tokushima University Institutional Repository) ● Metadata: 115605 (Link to Publication Site) ● Publication site (DOI): 10.3390/molecules25071725 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32283709 ● Summary page in Scopus @ Elsevier: 2-s2.0-85083281974 (Tokushima University Institutional Repository: 115605, DOI: 10.3390/molecules25071725, PubMed: 32283709, Elsevier: Scopus)
44.	Tasuku Torao, Miyuki Mimura, Yasufumi Ohshima, Kohki Fujikawa, Mahadi Hasan, Tatsuharu Shimokawa, Naoshi Yamazaki, Hidenori ANDO, Tatsuhiro Ishida, Tatsuya Fukuta, Tamotsu Tanaka and Kentaro Kogure : Characteristics of unique endocytosis induced by weak current for cytoplasmic drug delivery, International Journal of Pharmaceutics, Vol.576, 119010, 2020. (Tokushima University Institutional Repository) ● Metadata: 114728 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijpharm.2019.119010 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.ijpharm.2019.119010 (Tokushima University Institutional Repository: 114728, DOI: 10.1016/j.ijpharm.2019.119010)
45.	Emam Emam Abdallah Sherif, Lila Selim Ahmed Ali Abu Amr, Elhewan Emam Elsadek Emam Ali Nehal, Hidenori ANDO, Taro Shimizu, Keiichiro Okuhira, Yu Ishima, M Mahdy, E Ghazy and Tatsuhiro Ishida : Cancer cell-type tropism is one of crucial determinants for the efficient systemic delivery of cancer cell-derived exosomes to tumor tissues, European Journal of Pharmaceutics and Biopharmaceutics, Vol.145, 27-34, 2019. (Summary) Exosomes are gaining increasing attention as drug delivery vehicles due to their low toxicity and ability to functionally transfer biological cargos between cells. However, the therapeutic applicability of exosomes is partially hampered by a lack of cell-type specificity. In this study, therefore, we investigated the impact of cell-type tropism on the in vivo systemic delivery of exosomes to tumor tissues. Exosomes derived from murine colorectal cancer cells (C26) (C26-Exos) and murine melanoma cells (B16BL6) (B16BL6-Exos) were collected. In vitro cellular uptake of either autologous (C26) or allogeneic (B16BL6) exosomes by C26 tumor cells was determined. In vivo tumor accumulation of each type of exosomes in mice bearing C26 tumors was monitored with an in vivo imaging system (IVIS). In in vitro studies, autologous C26-Exos were more efficiently taken up by C26 cancer cells, compared to allogeneic B16BL6-Exos. For in vivo studies, exosomes were modified with surface polyethylene glycol (PEG) to improve their circulation lifetimes. Although both types of PEGylated exosomes accumulated in C26-tumor tissue, autologous exosomes were preferentially accumulated within C26-tumor tissue compared to allogeneic exosomes. The increased tumor accumulation of autologous PEGylated exosomes was accompanied by the preferential uptake of exosomes by not only C26-tumor cells but also tumor-associated immune cells. This study implies that cancer cell-type tropism is an important factor in the achievement of tumor cell targeting with cancer cell-derived exosomes. (Keyword) Animals / Cell Line, Tumor / Colorectal Neoplasms / Drug Delivery Systems / Exosomes / Male / Melanoma / Mice / Mice, Inbred BALB C / Polyethylene Glycols / Tropism (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ejpb.2019.10.005 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31629787 ● Summary page in Scopus @ Elsevier: 2-s2.0-85073758566 (DOI: 10.1016/j.ejpb.2019.10.005, PubMed: 31629787, Elsevier: Scopus)
46.	Hidenori ANDO, M Fukushima, K Eshima, Taichi Hasui, Taro Shimizu, Yu Ishima, C Huang, H Wada and Tatsuhiro Ishida : A novel intraperitoneal therapy for gastric cancer with DFP-10825, a unique RNAi therapeutic targeting thymidylate synthase, in peritoneally disseminated xenograft model, Cancer Medicine, Vol.8, No.17, 7313-7321, 2019. (Summary) In advanced gastric cancer, peritoneal dissemination is a life-threatening mode of metastasis. Since the treatment options with conventional chemotherapy remain limited, any novel therapeutic strategy that could control such metastasis would improve the outcome of treatment. We recently developed a unique RNA interference therapeutic regimen (DFP-10825) consisting of short hairpin RNA against thymidylate synthase (TS shRNA) and cationic liposomes. The treatment with DFP-10825 has shown remarkable antitumor activity in peritoneally disseminated human ovarian cancer-bearing mice via intraperitoneal administration. In this study, we expanded DFP-10825 to the treatment of peritoneally disseminated gastric cancer. DFP-10825 was administered intraperitoneally into mice with intraperitoneally implanted human gastric cancer cells (MKN45 or NCI-N87). Antitumor activity and host survival benefits were monitored. Intraperitoneal distribution of fluorescence-labeled DFP-10825 was monitored in this MKN45 peritoneally disseminated mouse model. Intraperitoneal injection of DFP-10825 suppressed tumor growth in two peritoneally disseminated cancer models (MKN45 and NCI-N87) and increased the survival time of the MKN45 model without severe side effects. Throughout the treatment regimen, no significant body weight loss was associated with the administration of DFP-10825. Interestingly, after intraperitoneal injection, fluorescence-labeled DFP-10825 retained for more than 72 hours in the peritoneal cavity and selectively accumulated in disseminated tumors. Intraperitoneal injection of DFP-10825 demonstrated effective antitumor activity without systemic severe adverse effects via the selective delivery of RNAi molecules into disseminated tumors in the peritoneal cavity. Our current study indicates that DFP-10825 could become an alternative option to improve the outcomes of patients with peritoneally disseminated gastric cancer. (Tokushima University Institutional Repository) ● Metadata: 115036 (Link to Publication Site) ● Publication site (DOI): 10.1002/cam4.2598 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31609087 ● Search Scopus @ Elsevier (PMID): 31609087 ● Search Scopus @ Elsevier (DOI): 10.1002/cam4.2598 (Tokushima University Institutional Repository: 115036, DOI: 10.1002/cam4.2598, PubMed: 31609087)
47.	Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : PEG修飾リポソームに対する免疫応答, 人工血液, Vol.27, 37-43, 2019.
48.	Hiroyuki Koide, Tatsuya Fukuta, Anna Okishim, Saki Ariizumi, Chiaki Kiyokawa, Hiroki Tsuchida, Masahiko Nakamoto, Keiichi Yoshimatsu, Hidenori ANDO, Takehisa Dewa, Tomohiro Asai, Naoto Oku, Yu Hoshino and Kenneth J. Shea : Engineering the binding kinetics of synthetic polymer nanoparticles for siRNA delivery, Biomacromolecules, Vol.20, No.10, 3648-3657, 2019. (Summary) The affinity of a synthetic polymer nanoparticle (NP) to a target biomacromolecule is determined by the association and dissociation rate constants (, ) of the interaction. The individual rates and their sensitivity to local environmental influences are important factors for the on-demand capture and release a target biomacromolecule. Positively charged NPs for small interfering RNA (siRNA) delivery is a case in point. The knockdown efficacy of siRNA can be strongly influenced by the binding kinetics to the NP. Here, we show that and of siRNA to NPs can be individually engineered by tuning the chemical structure and composition of the NP. -Isopropylacrylamide-based NPs functionalized with hydrophobic and amine monomers were used. decreased by increasing the amount of amine groups in the NP, whereas did not change. Importantly, NPs showing a low at pH 5.5 together with a high at pH 7.4 showed high knockdown efficiency when NP/siRNA complexes were packaged in lipid nanoparticles. These results provide direct evidence for the premise that the efficacy of an siRNA delivery vector is linked with the strong affinity to the siRNA in the endosome and low affinity in the cytoplasm. (Link to Publication Site) ● Publication site (DOI): 10.1021/acs.biomac.9b00611 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31518109 ● Summary page in Scopus @ Elsevier: 2-s2.0-85073096311 (DOI: 10.1021/acs.biomac.9b00611, PubMed: 31518109, Elsevier: Scopus)
49.	Hidenori ANDO, Lila Selim Ahmed Ali Abu Amr, M Fukushima, Rie Matsuoka, Taro Shimizu, Keiichiro Okuhira, Yu Ishima, C Huang, H Wada and Tatsuhiro Ishida : A simplified method for manufacturing RNAi therapeutics for local administration, International Journal of Pharmaceutics, Vol.564, 256-262, 2019. (Summary) RNA interference (RNAi) is one of the most promising strategies for cancer therapeutics. The successful translation of RNAi therapeutics to a clinic setting requires a delivery system that is efficient and simple to upscale. In this study, we devised a simple industrial method to manufacture lipoplex, which includes short hairpin RNA against the expression of thymidylate synthase (TS shRNA) - a key molecule for DNA biosynthesis. An aqueous solution of TS shRNA was gently mixed with either a precursor of cationic liposome (Presome DF-1) or a cationic lipid mixture in an o/w emulsion. This solution was subsequently lyophilized under optimal conditions to obtain either FD-lipoplex-1 or FD-lipoplex-2, respectively. With this method, a lipoplex in activated form was obtained via a simple "one-step" hydration with saline. Both forms of FD-lipoplex showed physicochemical properties comparable to those of conventional lipoplex. FD-lipoplexes stably retained TS shRNA within their formulations in the presence of tumor ascites fluid. Intraperitoneal treatment with either FD-lipoplex-1 or FD-lipoplex-2 provided a therapeutic level of efficacy comparable to that of conventional lipoplex in the treatment of a peritoneal disseminated gastric cancer mouse model. Collectively, established freeze-drying-based methods for RNAi-therapeutic preparation could realistically be used in a clinical setting for the treatment of patients with peritoneal disseminated cancer. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijpharm.2019.04.054 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31015002 ● Summary page in Scopus @ Elsevier: 2-s2.0-85064496754 (DOI: 10.1016/j.ijpharm.2019.04.054, PubMed: 31015002, Elsevier: Scopus)
50.	Mayumi Ikeda, Yu Ishima, VTG Chuang, Maki Sakai, Hiroki Osafune, Hidenori ANDO, Taro Shimizu, Keiichiro Okuhira, H Watanabe, T Maruyama, M Otagiri, T Akaike and Tatsuhiro Ishida : Distribution of Polysulfide in Human Biological Fluids and Their. Association with Amylase and Sperm Activities, Molecules, Vol.24, No.9, 1689, 2019. (Summary) Intracellular polysulfide could regulate the redox balance via its anti-oxidant activity. However, the existence of polysulfide in biological fluids still remains unknown. Recently, we developed a quantitative analytical method for polysulfide and discovered that polysulfide exists in plasma and responds to oxidative stress. In this study, we confirmed the presence of polysulfide in other biological fluids, such as semen and nasal discharge. The levels of polysulfide in these biological fluids from healthy volunteers ( = 9) with identical characteristics were compared. Additionally, the circadian rhythm of plasma polysulfide was also investigated. The polysulfide levels detected from nasal discharge and seminal fluid were approximately 400 and 600 μM, respectively. No correlation could be found between plasma polysulfide and the polysulfide levels of tear, saliva, and nasal discharge. On the other hand, seminal polysulfide was positively correlated with plasma polysulfide, and almost all polysulfide contained in semen was found in seminal fluid. Intriguingly, saliva and seminal polysulfide strongly correlated with salivary amylase and sperm activities, respectively. These results provide a foundation for scientific breakthroughs in various research areas like infertility and the digestive system process. (Tokushima University Institutional Repository) ● Metadata: 115606 (Link to Publication Site) ● Publication site (DOI): 10.3390/molecules24091689 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31052207 ● Summary page in Scopus @ Elsevier: 2-s2.0-85065659717 (Tokushima University Institutional Repository: 115606, DOI: 10.3390/molecules24091689, PubMed: 31052207, Elsevier: Scopus)
51.	Taro Shimizu, Lila Selim Ahmed Ali Abu Amr, Mizuki Awata, Yukiyo Kubo, Yu Mima, Yosuke Hashimoto, Hidenori ANDO, Keiichiro Okuhira, Yu Ishima and Tatsuhiro Ishida : A cell assay for detecting anti-PEG immune response against PEG-modified therapeutics, Pharmaceutical Research, Vol.35, No.11, 223, 2018. (Summary) Immunogenicity of PEGylated proteins and nanomedicines represents a potential impediment against their development and use in clinical settings. The purpose of this study is to develop a method for detecting anti-PEG immunity of PEGylated proteins and/or nanomedicines using flow cytometry. The binding of fluorescence-labeled mPEG-modified liposomes to HIK-G11 cells, PEG-specific hybridoma cells, or spleen cells was evaluated by flow cytometry for detecting immunogenicity of PEGylated therapeutics. The fluorescence-labeled methoxy PEG (mPEG)-modified liposomes were efficiently bound to HIK-G11 cells. Such staining with fluorescence-labeled mPEG-modified liposomes was significantly inhibited in the presence of either non-labeled mPEG-modified liposomes or mPEG-modified ovalbumin (OVA) but not polyglycerol-modified liposomes. In addition, we found that mPEG-modified liposomes, highly immunogenic, caused proliferation of PEG-specific cells, while hydroxyl PEG-modified liposomes, less immunogenic, scarcely caused. Furthermore, after intravenous injection of mPEG-modified liposomes, the percentage of PEG-specific cells in the splenocytes, as determined by flow cytometry, corresponded well with the production level of anti-PEG antibodies, as determined by ELISA. PEG-specific B cell assay we introduced may become a useful method to detect an anti-PEG immune response against PEGylated therapeutics and clarify the mechanism for anti-PEG immune responses. (Link to Publication Site) ● Publication site (DOI): 10.1007/s11095-018-2505-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30280273 ● Summary page in Scopus @ Elsevier: 2-s2.0-85054175366 (DOI: 10.1007/s11095-018-2505-3, PubMed: 30280273, Elsevier: Scopus)
52.	Emam Emam Abdallah Sherif, Hidenori ANDO, Lila Selim Ahmed Ali Abu Amr, Taro Shimizu, Keiichiro Okuhira, Yu Ishima, M Mahdy, F Ghazy, I Sagawa and Tatsuhiro Ishida : Liposome co-incubation with cancer cells secreted exosomes (extracellular vesicles) with different proteins expressions and different uptake pathways, Scientific Reports, Vol.8, No.1, 14493, 2018. (Summary) We recently showed that in vitro incubation of cells with liposomes of varying compositions can increase exosome secretion and increase the yield of harvested exosomes (extracellular vesicles, EVs). This might foster their potential therapeutic implementations. In the current study, we investigated the surface proteins and the uptake of the harvested exosomes (EVs) to see if the incubation of cells with liposomes would change the biological properties of these exosomes (EVs). Interestingly, exosomes (EVs) induced by solid cationic liposomes lacked some major exosome marker proteins such as CD9, flotillin-1, annexin-A2 and EGF, and subsequently had lower levels of cellular uptake upon re-incubation with donor cancer cells. However, exosomes (EVs) induced under normal condition and by fluid cationic liposomes, displayed the entire spectrum of proteins, and exhibited higher uptake by the donor cancer cells. Although endocytosis was the major uptake pathway of exosomes (EVs) by tumor cells, endocytosis could occur via more than one mechanism. Higher exosome uptake was observed in donor B16BL6 cells than in allogeneic C26 cells, indicating that donor cells might interact specifically with their exosomes (EVs) and avidly internalize them. Taken together, these results suggest a technique for controlling the characteristics of secreted exosomes (EVs) by incubating donor cancer cells with liposomes of varying physiochemical properties. (Tokushima University Institutional Repository) ● Metadata: 114955 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-018-32861-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30262875 ● Summary page in Scopus @ Elsevier: 2-s2.0-85054056121 (Tokushima University Institutional Repository: 114955, DOI: 10.1038/s41598-018-32861-w, PubMed: 30262875, Elsevier: Scopus)
53.	Emam Emam Abdallah Sherif, Hidenori ANDO, Lila Selim Ahmed Ali Abu Amr, Shinya Kobayashi, Taro Shimizu, Keiichiro Okuhira, Yu Ishima and Tatsuhiro Ishida : Doxorubicin expands in vivo secretion of circulating exosome in mice, Biological & Pharmaceutical Bulletin, Vol.41, No.7, 1078-1083, 2018. (Summary) Modulation of tumor immunity is a known factor in the antitumor activity of many chemotherapeutic agents. Exosomes are extracellular nanometric vesicles that are released by almost all types of cells, which includes cancer cells. These vesicles play a crucial role in tumor immunity. Many in vitro studies have reproduced the aggressive secretion of exosomes following treatment with conventional anticancer drugs. Nevertheless, how chemotherapeutic agents including nanomedicines such as Doxil affect the in vivo secretion of exosomes is yet to be elucidated. In this study, the effect of intravenous injection of either free doxorubicin (DXR) or liposomal DXR formulation (Doxil) on exosome secretion was evaluated in BALB/c mice. Exosomes were isolated from serum by using an ExoQuick™ kit. Free DXR treatment markedly increased serum exosome levels in a post-injection time-dependent manner, while Doxil treatment did not. Exosomal size distribution and marker protein expressions (CD9, CD63, and TSG101) were studied. The physical/biological characteristics of treatment-induced exosomes were comparable to those of control mice. Interestingly, splenectomy significantly suppressed the copious exosomal secretions induced by free DXR. Collectively, our results indicate that conventional anticancer agents induce the secretion of circulating exosomes, presumably via stimulating immune cells of the spleen. As far as we know, this study represents the first report indicating that conventional chemotherapeutics may induce exosome secretion which might, in turn, contribute partly to the antitumor effect of chemotherapeutic agents. (Keyword) Animals / Antibiotics, Antineoplastic / Doxorubicin / Exocytosis / Exosomes / Injections, Intravenous / Male / Mice / Mice, Inbred BALB C / Models, Animal / Polyethylene Glycols / Spleen (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b18-00202 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29962402 ● Summary page in Scopus @ Elsevier: 2-s2.0-85049360539 (DOI: 10.1248/bpb.b18-00202, PubMed: 29962402, Elsevier: Scopus)
54.	Emam Emam Abdallah Sherif, Hidenori ANDO, Lila Selim Ahmed Ali Abu Amr, Taro Shimizu, Masami Ukawa, Keiichiro Okuhira, Yu Ishima, A M Mahdy, S F Ghazy and Tatsuhiro Ishida : A novel strategy to increase the yield of exosomes (extracellular vesicles) for an expansion of basic research, Biological & Pharmaceutical Bulletin, Vol.41, No.5, 733-742, 2018. (Summary) Exosomes are tiny extracellular vesicles that are usually harvested in small quantities. Such small yield has been an obstacle for the expansion of the basic research regarding exosome analysis and applications in drug delivery. To increase exosome yield, we attempted to stimulate tumor cells via the addition of liposomes in vitro. Neutral, cationic-bare or PEGylated liposomes were incubated with four different tumor cell lines. The stimulatory effect of liposomal formulations on exosome secretion and cellular uptake propensity of the collected exosome by mother cells or different cells was evaluated. Both neutral and cationic-bare liposomes enhanced exosome secretion in a dose-dependent manner. Fluid cationic liposomes provided the strongest stimulation. Surprisingly, the PEGylation of bare liposomes diminished exosome secretion. Exosomes harvested in the presence of fluid cationic liposomes showed increased cellular uptake, but solid cationic liposomes did not. Our findings indicate that the physicochemical properties of liposomes determine whether they will act as a stimulant or as a depressant on exosome secretion from tumor cells. Liposomal stimulation may be a useful strategy to increase exosome yield, although further preparation to increase the purity of exosomes may be needed. In addition, fine-tuning of the biological properties of induced exosomes could be achieved via controlling the physicochemical properties of the stimulant liposomes. (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b17-00919 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29709910 ● Summary page in Scopus @ Elsevier: 2-s2.0-85046668949 (DOI: 10.1248/bpb.b17-00919, PubMed: 29709910, Elsevier: Scopus)
55.	Hidenori ANDO, Lila Selim Ahmed Ali Abu Amr, Masao Tanaka, Yusuke Doi, Yasuko Terada, Naoto Yagi, Taro Shimizu, Keiichiro Okuhira, Yu Ishima and Tatsuhiro Ishida : Intratumoral visualization of oxaliplatin within a liposomal formulation using X-ray fluorescence spectrometry, Molecular Pharmaceutics, Vol.15, No.2, 403-409, 2018. (Summary) Microsynchrotron radiation X-ray fluorescence spectrometry (-SR-XRF) is an X-ray procedure that utilizes synchrotron radiation as an excitation source. -SR-XRF is a rapid, nondestructive technique that allows mapping and quantification of metals and biologically important elements in cell or tissue samples. Generally, the intratumor distribution of nanocarrier-based therapeutics is assessed by tracing the distribution of a labeled nanocarrier within tumor tissue, rather than by tracing the encapsulated drug. Instead of targeting the delivery vehicle, we employed -SR-XRF to visualize the intratumoral microdistribution of oxaliplatin (l-OHP) encapsulated within PEGylated liposomes. Tumor-bearing mice were intravenously injected with either l-OHP-containing PEGylated liposomes (l-OHP liposomes) or free l-OHP. The intratumor distribution of l-OHP within tumor sections was determined by detecting the fluorescence of platinum atoms, which are the main elemental components of l-OHP. The l-OHP in the liposomal formulation was localized near the tumor vessels and accumulated in tumors at concentrations greater than those seen with the free form, which is consistent with the results of our previous study that focused on fluorescent labeling of PEGylated liposomes. In addition, repeated administration of l-OHP liposomes substantially enhanced the tumor accumulation and/or intratumor distribution of a subsequent dose of l-OHP liposomes, presumably via improvements in tumor vascular permeability, which is also consistent with our previous results. In conclusion, -SR-XRF imaging efficiently and directly traced the intratumor distribution of the active pharmaceutical ingredient l-OHP encapsulated in liposomes within tumor tissue. -SR-XRF imaging could be a powerful means for estimating tissue distribution and even predicting the pharmacological effect of nanocarrier-based anticancer metal compounds. (Link to Publication Site) ● Publication site (DOI): 10.1021/acs.molpharmaceut.7b00762 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29287147 ● Summary page in Scopus @ Elsevier: 2-s2.0-85041697937 (DOI: 10.1021/acs.molpharmaceut.7b00762, PubMed: 29287147, Elsevier: Scopus)
56.	Hidenori ANDO, Lila Selim Ahmed Ali Abu Amr, Munehira Kawanishi, Taro Shimizu, Keiichiro Okuhira, Yu Ishima and Tatsuhiro Ishida : Reactivity of IgM antibodies elicited by PEGylated liposomes or PEGylated lipoplexes against auto and foreign antigens, Journal of Controlled Release, Vol.270, 114-119, 2018. (Summary) Polyethylene glycol (PEG) is an attractive tool for the development of nanoparticle-based cancer therapy since it endows nanoparticles with extended-circulation properties. Nevertheless, recent reports have revealed that intravenous injection of either PEGylated liposomes (SLs) or PEGylated lipoplex (PLpx) could elicit an anti-PEG immunoglobulin (IgM) response in a T cell-independent (TI) manner that would substantially compromise the in vivo fate of PEGylated products upon repeated administration. In the same context, viral or bacterial infections trigger the production of polyreactive IgM that binds both self and foreign antigens. The polyreactivity of IgM elicited by SLs or PLpx, to bacteria and other polymers, however, is yet to be elucidated. In this study, the polyreactivity of IgM elicited by SLs or PLpx was challenged against different bacteria (TI antigens) and against synthetic polymer composed of repetitive structures (PVP-360 or FITC-dextran). Results demonstrated that anti-PEG IgM elicited by either SLs or PLpx showed no reactivity to various bacteria examined, while the IgM showed remarkable reactivity to both PVP-360 and FITC-dextran. In addition, interestingly, anti-PEG IgM elicited by either SLs or PLpx showed no antinuclear antibody-like immune reactivity, and, therefore, treatment with either SLs or PLpx was not expected to exacerbate autoimmune diseases such as systemic lupus erythematosus. Collectively, our findings could provide information supporting the safety of PEGylated nanoparticle-based pharmaceutics, particularly in patients with autoimmune diseases. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jconrel.2017.12.002 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29217175 ● Summary page in Scopus @ Elsevier: 2-s2.0-85037534004 (DOI: 10.1016/j.jconrel.2017.12.002, PubMed: 29217175, Elsevier: Scopus)
57.	Hidenori ANDO and Tatsuhiro Ishida : 放射光施設(SPring-8)における蛍光X線分析法を用いたオキサリプラチン腫瘍内分布解析, Journal of Pharmaceutical Science and Technology, Japan, Vol.78, No.1, 28-33, 2018. (Link to Publication Site) ● Publication site (DOI): 10.14843/jpstj.78.28 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001205741139840 ● Search Scopus @ Elsevier (DOI): 10.14843/jpstj.78.28 (DOI: 10.14843/jpstj.78.28, CiNii: 1390001205741139840)
58.	Kentaro Nishida, Misaki Kashiwagi, Shunsuke Shiba, Kiwamu Muroki, Akihiro Ohishi, Yusuke Doi, Hidenori ANDO, Tatsuhiro Ishida and Kazuki Nagasawa : Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity, Toxicology and Applied Pharmacology, Vol.337, 76-84, 2017. (Summary) Liposomalization causes alteration of the pharmacokinetics of encapsulated drugs, and allows delivery to tumor tissues through passive targeting via an enhanced permeation and retention (EPR) effect. PEGylated liposomal doxorubicin (Doxil(®), Lipo-DXR), a representative liposomal drug, is well-known to reduce cardiotoxicity and increase the anti-tumor activity of DXR, but to induce the hand-foot syndrome (HFS) as a result of skin DXR accumulation, which is one of its severe adverse effects. We have developed a new liposomal preparation of oxaliplatin (l-OHP), an important anti-tumor drug for treatment of colorectal cancer, using PEGylated liposomes (Lipo-l-OHP), and showed that Lipo-l-OHP exhibits increased anti-tumor activity in tumor-bearing mice compared to the original preparation of l-OHP. However, whether Lipo-l-OHP causes HFS-like skin toxicity similar to Lipo-DXR remains to be determined. Administration of Lipo-l-OHP promoted accumulation of platinum in rat hind paws, however, it caused negligible morphological and histological alterations on the plantar surface of the paws. Administration of DiI-labeled empty PEGylated liposomes gave almost the same distribution profile of dyes into the dermis of hind paws with DXR as in the case of Lipo-DXR. Treatment with Lipo-l-OHP, Lipo-DXR, DiI-labeled empty PEGylated liposomes or empty PEGylated liposomes caused migration of CD68(+) macrophages into the dermis of hind paws. These findings suggest that the skin toxicity on administration of liposomalized drugs is reflected in the proinflammatory characteristics of encapsulated drugs, and indicate that Lipo-l-OHP with a higher anti-cancer effect and no HFS may be an outstanding l-OHP preparation leading to an improved quality of life of cancer patients. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.taap.2017.10.006 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29054682 ● Summary page in Scopus @ Elsevier: 2-s2.0-85032786660 (DOI: 10.1016/j.taap.2017.10.006, PubMed: 29054682, Elsevier: Scopus)
59.	Taro Shimizu, Lila Selim Ahmed Ali Abu Amr, Miho Nishio, Yusuke Doi, Hidenori ANDO, Masami Ukawa, Yu Ishima and Tatsuhiro Ishida : Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatin in mouse model, Cancer Science, Vol.108, No.9, 1864-1869, 2017. (Summary) Immune modulation of the tumor microenvironment has been reported to participate in the therapeutic efficacy of many chemotherapeutic agents. Recently, we reported that liposomal encapsulation of oxaliplatin (l-OHP) within PEGylated liposomes conferred a superior antitumor efficacy to free l-OHP in murine colorectal carcinoma-bearing mice through permitting preferential accumulation of the encapsulated drug within tumor tissue. However, the contribution of the immune-modulatory properties of liposomal l-OHP and/or free l-OHP to the overall antitumor efficacy was not elucidated. In the present study, therefore, we investigated the effect of liposomal encapsulation of l-OHP within PEGylated liposomes on the antitumor immunity in both immunocompetent and immunodeficient mice. Liposomal l-OHP significantly suppressed the growth of tumors implanted in immunocompetent mice, but not in immunodeficient mice. In immunocompetent mice, liposomal l-OHP increased the tumor MHC-1 level and preserved antitumor immunity through decreasing the number of immune suppressor cells, including regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages, which collectively suppress CD8(+) T cell-mediated tumor cells killing. In contrast, free l-OHP ruined antitumor immunity. These results suggest that the antitumor efficacy of liposomal l-OHP is attributed, on the one hand, to its immunomodulatory effect on tumor immune microenvironment that is superior to that of free l-OHP, and on the other hand, to its direct cytotoxic effect on tumor cells. (Tokushima University Institutional Repository) ● Metadata: 112372 (Link to Publication Site) ● Publication site (DOI): 10.1111/cas.13305 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28643902 ● Search Scopus @ Elsevier (PMID): 28643902 ● Search Scopus @ Elsevier (DOI): 10.1111/cas.13305 (Tokushima University Institutional Repository: 112372, DOI: 10.1111/cas.13305, PubMed: 28643902)
60.	Alaaeldin Eman, Lila Selim Ahmed Ali Abu Amr, Hidenori ANDO, M Fukushima, C Huang, H Wada, H.A Sarhan, K.A Khaled and Tatsuhiro Ishida : Co-administration of liposomal l-OHP and PEGylated TS shRNA-lipoplex: A novel approach to enhance anti-tumor efficacy and reduce the immunogenic response to RNAi molecules, Journal of Controlled Release, Vol.255, 210-217, 2017. (Summary) Many therapeutic strategies have been applied in efforts to conquer the development and/or progression of cancer. The combination of chemotherapy and an RNAi-based approach has proven to be an efficient anticancer therapy. However, the feasibility of such a therapeutic strategy has been substantially restricted either by the failure to achieve the efficient delivery of RNAi molecules to tumor tissue or by the immunostimulatory response triggered by RNAi molecules. In this study, therefore, we intended to investigate the efficacy of using liposomal oxaliplatin (liposomal l-OHP) to guarantee the efficient delivery of RNAi molecules, namely shRNA against thymidylate synthase (TS shRNA) complexed with cationic liposome (TS shRNA-lipoplex), to solid tumors, and to suppress the immunostimulatory effect of RNAi molecules, TS shRNA, following intravenous administration. Herein, we describe how liposomal l-OHP enhanced the intra-tumor accumulation of TS shRNA-lipoplex and significantly reduced the immunostimulatory response triggered by TS shRNA. Consequently, such enhanced accumulation of TS shRNA-lipoplex along with the cytotoxic effect of liposomal l-OHP led to a remarkable tumor growth suppression (compared to mono-therapy) following systemic administration. Our results, therefore, may have important implications for the provision of a safer and more applicable combination therapy of RNAi molecules and anti-cancer agents that can produce a more reliable anti-tumor effect. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jconrel.2017.04.040 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28461099 ● Search Scopus @ Elsevier (PMID): 28461099 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jconrel.2017.04.040 (DOI: 10.1016/j.jconrel.2017.04.040, PubMed: 28461099)
61.	Mayumi Ikeda, Yu Ishima, Akitomo Shibata, Victor T.G. Chuang, Tomohiro Sawa, Hideshi Ihara, Hiroshi Watanabe, Ming Xian, Yuya Ouchi, Taro Shimizu, Hidenori ANDO, Masami Ukawa, Tatsuhiro Ishida, T Akaike, M Otagiri and T Maruyama : Quantitative determination of polysulfide in albumins, plasma proteins and biological fluid samples using a novel combined assays approach, Analytica Chimica Acta, Vol.969, 18-25, 2017. (Summary) Hydrogen sulfide (H2S) signaling involves polysulfide (RSSnSR') formation on various proteins. However, the current lack of sensitive polysulfide detection assays poses methodological challenges for understanding sulfane sulfur homeostasis and signaling. We developed a novel combined assay by modifying Sulfide Antioxidant Buffer (SAOB) to produce an "Elimination Method of Sulfide from Polysulfide" (EMSP) treatment solution that liberates sulfide, followed with methylene blue (MB) sulfide detection assay. The combined EMSP-MB sulfide detection assay performed on low molecular weight sulfur species showed that sulfide was produced from trisulfide compounds such as glutathione trisulfide and diallyl trisulfide, but not from the thiol compounds such as cysteine, cystine and glutathione. In the case of plasma proteins, this novel combined detection assay revealed that approximately 14.7, 1.7, 3.9, 3.7 sulfide mol/mol released from human serum albumin, 1-anti-trypsin, 1-acid glycoprotein and ovalbumin, respectively, suggesting that serum albumin is a major pool of polysulfide in human blood circulation. Taken together with the results of albumins of different species, the liberated sulfide has a good correlation with cysteine instead of methionine, indicating the site of incorporation of polysulfide is cysteine. With this novel sulfide detention assay, approximately 8,000, 120 and 1100 M of polysulfide concentrations was quantitated in human healthy plasma, saliva and tear, respectively. Our promising polysulfide specific detection assay can be a very important tool because quantitative determination of polysulfide sheds light on the functional consequence of protein-bound cysteine polysulfide and expands the research area of reactive oxygen to reactive polysulfide species. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.aca.2017.03.027 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28411626 ● Summary page in Scopus @ Elsevier: 2-s2.0-85017155399 (DOI: 10.1016/j.aca.2017.03.027, PubMed: 28411626, Elsevier: Scopus)
62.	Yu Mima, Lila Selim Ahmed Ali Abu Amr, Taro Shimizu, Masami Ukawa, Hidenori ANDO, Yasuko Kurata and Tatsuhiro Ishida : Ganglioside inserted into PEGylated liposome attenuates anti-PEG immunity, Journal of Controlled Release, Vol.250, 20-26, 2017. (Summary) Despite the clinical introduction of a vast number of polyethylene glycol (PEG)-conjugated therapeutics, conjugated PEG is also known for an unfortunate inclination toward immunogenicity. Immunogenicity of PEG, manifested by the robust production of anti-PEG IgM, is known to compromise the therapeutic efficacy and/or reduce the tolerance of PEGylated therapeutics. In the present study, we inserted ganglioside into the membrane of PEGylated liposome (PL) to prepare ganglioside-modified PEGylated liposomes (G-PL), and investigated its efficacy in attenuating the anti-PEG IgM response against PL. A single intravenous injection of G-PL significantly attenuated the anti-PEG IgM production, compared with that of naïve PL. In addition, pretreatment with G-PL substantially alleviated the anti-PEG IgM response elicited by a subsequent dose of PL, presumably via inducing B cell tolerance, and as a consequence, this modification abrogated/attenuated the incidence of the rapid clearance of subsequently administrated PL. These results indicate that incorporating gangliosides in PEGylated liposome membrane not only prevents the immunogenicity of PEG but also induces the tolerance of B cells to subsequent doses of the immunogenic PL. Consequently, liposomal membrane modification with ganglioside might represent a promising approach to attenuating the immunogenicity of PEGylated liposomes while preserving their therapeutic efficacy, particularly upon repeated administration. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jconrel.2017.01.040 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28179196 ● Summary page in Scopus @ Elsevier: 2-s2.0-85011965687 (DOI: 10.1016/j.jconrel.2017.01.040, PubMed: 28179196, Elsevier: Scopus)
63.	Takuma Takayama, Masami Ukawa, Yuki Kanazawa, Hidenori ANDO, Taro Shimizu and Tatsuhiro Ishida : Hydrodynamic tail vein injection as a simple tool for yielding extended transgene expression in solid tumors., Biological & Pharmaceutical Bulletin, Vol.39, No.9, 1555-1558, 2016. (Summary) Hydrodynamic tail vein injection was considered an in vivo transfection method that yields a higher level of gene expression mainly in the liver. This method has been applied to cancer gene therapy targeting both hepatic and non-hepatic cancers. However, intratumor transgene expression in non-hepatic tumors has not been well studied. In this study, we showed an extended transgene expression of -galactosidase (LacZ), a nonsecretory protein, in a subcutaneously implanted murine solid tumor following the hydrodynamic injection of plasmid DNA (LacZ pDNA). Our result may indicate that the hydrodynamic injection method is a powerful tool that can be used to gain transgene expression not only in the liver but also in solid tumors. (Keyword) Animals / Cell Line, Tumor / DNA / Gene Expression / Gene Transfer Techniques / Genetic Therapy / Injections, Intravenous / Liver / Male / Mice / Mice, Inbred BALB C / Neoplasms / Plasmids / Tail / Transgenes / beta-Galactosidase (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b16-00283 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27582335 ● Summary page in Scopus @ Elsevier: 2-s2.0-84984698994 (DOI: 10.1248/bpb.b16-00283, PubMed: 27582335, Elsevier: Scopus)
64.	Masami Ukawa, Yukako Fujiwara, Hidenori ANDO, Taro Shimizu and Tatsuhiro Ishida : Hepatic tumor metastases cause enhanced PEGylated liposome uptake by Kupffer cells, Biological & Pharmaceutical Bulletin, Vol.39, No.2, 215-220, 2016. (Summary) Kupffer cells in livers bearing tumor metastases were found to have promoted tumor invasion and exacerbated the metastasis. This implies that the function of Kupffer cells might differ between animals bearing hepatic metastases and those that are healthy. Kupffer cells are considered responsible for the accumulation of liposomes in the liver. In this study, we hypothesized that the alteration in the function of Kupffer cells by hepatic metastasis would also affect the biodistribution of liposomes following intravenous administration. The hepatic accumulation and the blood concentration of PEGylated liposomes were compared between healthy mice and tumor-bearing mice. We noted that hepatic accumulation and elimination from the blood were significantly accelerated in tumor-bearing mice, indicating that our hypothesis was correct. In the tumor-bearing mice, the proportion of Kupffer cells taking up liposomes was significantly increased. Intravenous injection of oxaliplatin (l-OHP) containing PEGylated liposomes decreased the fraction of Kupffer cells, but this administration caused no injury to the hepatocytes. These results suggest that PEGylated liposomes containing l-OHP may have the potential to treat metastatic hepatic cancer-not only via the direct killing of the cancer cells but also via a reduction in tumor-supportive Kupffer cells. (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b15-00611 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26830481 ● Summary page in Scopus @ Elsevier: 2-s2.0-84958964867 (DOI: 10.1248/bpb.b15-00611, PubMed: 26830481, Elsevier: Scopus)
65.	Noriko Saito-Tarashima, Hidenori ANDO, Takamitsu Kojima, Nozomi Kinjo, Yosuke Hashimoto, Kazuhiro Furukawa, Tatsuhiro Ishida and Noriaki Minakawa : Gene silencing using 4'-thioDNA as an artificial template to synthesize short-hairpin RNA without inducing a detectable innate immune response, Molecular Therapy. Nucleic Acids, Vol.5, e274, 2016. (Summary) The development of a versatile technique to induce RNA interference (RNAi) without immune stimulation in vivo is of interest as existing approaches to trigger RNAi, such as small interfering RNA (siRNA) and plasmid DNA (pDNA) expressing short hairpin RNA (shRNA), present drawbacks arising from innate immune stimulation. To overcome them, an intelligent shRNA expression device (iRed) designed to induce RNAi was developed. The minimum sequence of iRed encodes only the U6 promoter and shRNA. A series of iRed comprises a polymerase chain reaction (PCR)-amplified 4'-thioDNA in which any one type of adenine (A), guanine (G), cytosine (C), or thymine (T) nucleotide unit was substituted by each cognate 4'-thio derivatives, i.e., dSA iRed, dSG iRed, dSC iRed, and ST iRed respectively. Each modified iRed acted as a template to transcribe shRNA with RNAi activity. The highest shRNA yield was generated using dSC iRed that exerted gene silencing activity in an orthotopic mouse model of mesothelioma. Reducing the minimal structure required to transcribe shRNA and the presence of the 4'-thiomodification synergistically function to abrogate innate immune response induced by dsDNA. The iRed will introduce a new approach to induce RNAi without inducing a detectable innate immune response. (Tokushima University Institutional Repository) ● Metadata: 110894 (Link to Publication Site) ● Publication site (DOI): 10.1038/mtna.2015.48 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26730811 ● Summary page in Scopus @ Elsevier: 2-s2.0-84953792236 (Tokushima University Institutional Repository: 110894, DOI: 10.1038/mtna.2015.48, PubMed: 26730811, Elsevier: Scopus)
66.	Hiroyuki Nakamura, Lila Selim Ahmed Ali Abu Amr, Miho Nishio, Masao Tanaka, Hidenori ANDO, Hiroshi Kiwada and Tatsuhiro Ishida : Intra-tumor distribution of PEGylated liposome upon repeated injection: No possession by prior dose, Journal of Controlled Release, Vol.220, 406-413, 2015. (Summary) Liposomes have proven to be a viable means for the delivery of chemotherapeutic agents to solid tumors. However, significant variability has been detected in their intra-tumor accumulation and distribution, resulting in compromised therapeutic outcomes. We recently examined the intra-tumor accumulation and distribution of weekly sequentially administered oxaliplatin (l-OHP)-containing PEGylated liposomes. In that study, the first and second doses of l-OHP-containing PEGylated liposomes were distributed diversely and broadly within tumor tissues, resulting in a potent anti-tumor efficacy. However, little is known about the mechanism underlying such a diverse and broad liposome distribution. Therefore, in the present study, we investigated the influence of dosage interval on the intra-tumor accumulation and distribution of "empty" PEGylated liposomes. Intra-tumor distribution of sequentially administered "empty" PEGylated liposomes was altered in a dosing interval-dependent manner. In addition, the intra-tumor distribution pattern was closely related to the chronological alteration of tumor blood flow as well as vascular permeability in the growing tumor tissue. These results suggest that the sequential administrations of PEGylated liposomes in well-spaced intervals might allow the distribution to different areas and enhance the total bulk accumulation within tumor tissue, resulting in better therapeutic efficacy of the encapsulated payload. This study may provide useful information for a better design of therapeutic regimens involving multiple administrations of nanocarrier drug delivery systems. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jconrel.2015.11.002 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26548975 ● Summary page in Scopus @ Elsevier: 2-s2.0-84946716430 (DOI: 10.1016/j.jconrel.2015.11.002, PubMed: 26548975, Elsevier: Scopus)
67.	Hidenori ANDO, Sakiko Kobayashi, Lila Selim Ahmed Ali Abu Amr, N Eldin Essam, Chihiro Katoh, Taro Shimizu, Masami Ukawa, Kazuyoshi Kawazoe and Tatsuhiro Ishida : Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed, Journal of Controlled Release, Vol.220, 29-36, 2015. (Summary) Malignant pleural mesothelioma (MPM) is an aggressive cancer that proliferates in the pleural cavity. Pemetrexed (PMX) in combination with cisplatin is currently the approved standard care for MPM, but a dismal response rate persists. Recently, we prepared various liposomal PMX formulations using different lipid compositions and evaluated their in vitro cytotoxicity against human mesothelioma cells (MSTO-211H). In the present study, we investigated the in vivo therapeutic effect of our liposomal PMX formulations using an orthotopic MPM tumor mouse model. PMX encapsulated within either cholesterol-containing (PMX/Chol CL) or cholesterol-free (PMX/Non-Chol CL) cationic liposome was intrapleurally injected into tumor-bearing mice. PMX encapsulated in cholesterol-free liposomes (PMX/Non-Chol CL) drastically inhibited the tumor growth in the pleural cavity, while free PMX and PMX encapsulated in cholesterol-containing liposomes (PMX/Chol CL) barely inhibited the tumor growth. The enhanced in vivo anti-tumor efficacy of PMX/Non-Chol CL was credited, on the one hand, for prolonging the retention of cationic liposomes in the pleural cavity via their electrostatic interaction with the negatively charged membranes of tumor cells, but on the other hand, it was charged with contributing to a higher drug release from the "fluid" liposomal membrane following intrapleural administration. This therapeutic strategy of direct intrapleural administration of liposomal PMX, along with the great advances in CL-guided therapeutics, might be a promising therapeutic approach to conquering the poor prognosis for MPM. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jconrel.2015.10.019 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26476173 ● Summary page in Scopus @ Elsevier: 2-s2.0-84944717805 (DOI: 10.1016/j.jconrel.2015.10.019, PubMed: 26476173, Elsevier: Scopus)
68.	Taro Shimizu, Yu Mima, Yosuke Hashimoto, Masami Ukawa, Hidenori ANDO, Hiroshi Kiwada and Tatsuhiro Ishida : Anti-PEG IgM and complement system are required for the association of second doses of PEGylated liposomes with splenic marginal zone B cells, Immunobiology, Vol.220, No.10, 1151-1160, 2015. (Summary) The accelerated blood clearance (ABC) phenomenon makes it crucial to use PEGylated liposomes and micelles to deliver drugs. The ABC phenomenon is an immune response against an initial dose of PEGylated liposome, which causes subsequent doses to be rapidly cleared by macrophages in the liver. We recently found that in the early phase of the ABC phenomenon, subsequent doses of PEGylated liposomes were associated with splenic marginal zone (MZ)-B cells and were transported from the MZ to the follicle (FO). In this study, we investigated the underlying mechanisms behind the association of subsequent doses of PEGylated liposomes with MZ-B cells in the spleen. Serum factors, anti-PEG IgM and complement system, were crucial to the association of PEGylated liposomes with MZ-B cells, while the sensitization of MZ-B cells by the first dose of PEGylated liposomes was not significant. It was the complement receptors (CRs) on the MZ-B cells, rather than either the PEG-specific B-cell receptors or the IgM Fc receptors, that were the main contributors to the association between PEGylated liposomes and MZ-B cells. It appeared that anti-PEG IgM would bind to PEGylated liposomes and causes subsequent complement activation, resulting in the formation of immune complexes of PEGylated liposome-anti-PEG IgM-complement. The MZ-B cells then recognized these immune complexes via their CRs. Such an association via CRs might have triggered the transport of the immune complex by MZ-B cells to the FO in the spleen. The information obtained in this study might be useful in the development of an efficient antigen delivery system to usher PEGylated nanoparticles into FO dendritic cells. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.imbio.2015.06.005 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26095176 ● Summary page in Scopus @ Elsevier: 2-s2.0-84937974851 (DOI: 10.1016/j.imbio.2015.06.005, PubMed: 26095176, Elsevier: Scopus)
69.	Noriko Saito-Tarashima, Tatsuya Sumitomo, Hidenori ANDO, Kazuhiro Furukawa, Tatsuhiro Ishida and Noriaki Minakawa : Synthesis of DNA fragments containing 2-deoxy-4-selenonucleoside units using DNA polymerases: comparison of dNTPs with O, S and Se at the 4-position in replication Org, Organic & Biomolecular Chemistry, Vol.13, No.25, 6949-6952, 2015. (Summary) 4'-SelenoDNA fragments were synthesized for the first time using 4'-selenothymidine triphosphate (SeTTP) by taking advantage of its bioequivalence against DNA polymerases. DNA fragments each with a homologous element (O, S or Se) at the 4'-position of the thymidine units were effectively amplified using KOD Dash DNA polymerase. (Link to Publication Site) ● Publication site (DOI): 10.1039/c5ob00941c (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26053864 ● Summary page in Scopus @ Elsevier: 2-s2.0-84934957265 (DOI: 10.1039/c5ob00941c, PubMed: 26053864, Elsevier: Scopus)

Review, Commentary:

1.	A Sherif Gaballa, Taro Shimizu, Hidenori ANDO, Haruka Takata, Sherif Abdallah Emam Emam, Eslam Mostafa Ramadan Abdelhameed, W Youssef Naguib, M Fatma Mady, A Khaled Khaled and Tatsuhiro Ishida : Treatment-induced and pre-existing anti-PEG antibodies: Prevalence, clinical implications, and future perspectives, Journal of Pharmaceutical Sciences, Vol.113, No.3, 555-578, Mar. 2024. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.xphs.2023.11.001 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.xphs.2023.11.001 (DOI: 10.1016/j.xphs.2023.11.001)
2.	Ibrahim Mohamed, Eslam Mostafa Ramadan Abdelhameed, Nehal Ali Emam Elsadek Emam Elhewan, Sherif Abdallah Emam Emam, Taro Shimizu, Hidenori ANDO, Yu Ishima, Elgarhy Helmy Omar, Sarhan A Hatem, Hussein K Amal and Tatsuhiro Ishida : Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products, Journal of Controlled Release, Vol.351, 215-230, Nov. 2022. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jconrel.2022.09.031 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.jconrel.2022.09.031 (DOI: 10.1016/j.jconrel.2022.09.031)
3.	Nana Matsuo, Hidenori ANDO, Yusuke Doi, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : The challenge to deliver oxaliplatin (l-OHP) to solid tumors: development of liposomal l-OHP formulations, Chemical & Pharmaceutical Bulletin, Vol.70, No.5, 351-358, May 2022. (Link to Publication Site) ● Publication site (DOI): 10.1248/cpb.c22-00099 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1248/cpb.c22-00099 (DOI: 10.1248/cpb.c22-00099)
4.	Hidenori ANDO : DDS抗がん剤の腫瘍内局在の解明と腫瘍微小環境改善による効果増強, Journal of the Pharmaceutical Society of Japan, Vol.141, No.11, 1241-1245, Nov. 2021. (Link to Publication Site) ● Publication site (DOI): 10.1248/yakushi.21-00148 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1248/yakushi.21-00148 (DOI: 10.1248/yakushi.21-00148)
5.	Hidenori ANDO and Tatsuhiro Ishida : An RNAi therapeutic, DFP-10825, for intraperitoneal and intrapleural malignant cancers, Advanced Drug Delivery Reviews, Vol.154-155, 27-36, Aug. 2020. (Summary) RNA interference (RNAi), a potent post-transcriptional gene-silencing action, has received considerable attentions as a novel therapeutic tool to treat intractable cancers. In recent days, we have developed a novel RNAi-based therapeutic formulation, DFP-10825, for the treatment of intractable advanced cancers developed in coelomic cavities. DFP-10825 was composed of chemically synthesized short hairpin RNA (shRNA) against thymidylate synthase (TS), a key enzyme for cancer proliferation, and cationic liposomes, and achieved high therapeutic effect on the mouse models of peritoneally disseminated gastric and ovarian cancers and malignant pleural mesothelioma without severe side effects by intracoelomic direct treatment. We further designed a freeze-dried DFP-10825 formulation for mass industrial production. DFP-10825 is undergoing in pre-clinical phase and goes to clinical trials. This review introduces a DFP-10825 formulation, a potent novel RNAi-based therapeutic maximizing the benefit of RNAi molecule (shRNA). (Link to Publication Site) ● Publication site (DOI): 10.1016/j.addr.2020.08.002 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32781056 ● Search Scopus @ Elsevier (PMID): 32781056 ● Search Scopus @ Elsevier (DOI): 10.1016/j.addr.2020.08.002 (DOI: 10.1016/j.addr.2020.08.002, PubMed: 32781056)
6.	Hidenori ANDO and Tatsuhiro Ishida : 臨床応用可能な体腔内投与型RNAi 製剤(DFP-10825)の開発と難治性がんに対する治療, Medchem News, Vol.30, No.1, 19-24, Feb. 2020. (Link to Publication Site) ● Publication site (DOI): 10.14894/medchem.30.1_19 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.14894/medchem.30.1_19 (DOI: 10.14894/medchem.30.1_19)
7.	Hidenori ANDO, Taro Shimizu and Tatsuhiro Ishida : リポソームDDS 製剤開発における免疫系の制御と動態解析の重要性, Oleoscience, Vol.20, No.2, 71-76, Feb. 2020. (Link to Publication Site) ● Publication site (DOI): 10.5650/oleoscience.20.71 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390283659849385728 ● Search Scopus @ Elsevier (DOI): 10.5650/oleoscience.20.71 (DOI: 10.5650/oleoscience.20.71, CiNii: 1390283659849385728)
8.	Hidenori ANDO, 田島健次, 松島得雄 and Tatsuhiro Ishida : ナノフィブリル化バクテリアセルロース(Fibnano)を用いた腹腔内投与型がん治療製剤への応用, Cellulose Communications, Vol.26, No.4, 173-177, Dec. 2019.
9.	田島健次, 小瀬亮太, 松島得雄, Tatsuhiro Ishida and Hidenori ANDO : フルーツ由来新奇酢酸菌によるナノセルロースの合成とその応用, Journal of The Brewing Society of Japan, Vol.114, No.9, 540-549, Sep. 2019. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050287462784741632 (CiNii: 1050287462784741632)
10.	Masami Ukawa, Hidenori ANDO, Taro Shimizu and Tatsuhiro Ishida : Pharmaceutics of Nanoparticles, Nanomaterials in Pharmacology, 219-238, Nov. 2015. (Link to Publication Site) ● Publication site (DOI): 10.1007/978-1-4939-3121-7_11 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1007/978-1-4939-3121-7_11 (DOI: 10.1007/978-1-4939-3121-7_11)

Proceeding of International Conference:

1.	Shoichiro Fukuda, Haruka Takata, Takashi Nakae, Noboru Tatsumi, Hidetoshi Hamamoto, Hidenori ANDO and Tatsuhiro Ishida : Enhanced effect of ionic liquid on intestinal absorption of macromolecules (< 10 kDa), 39th JSSX and 26th North American ISSX Meeting, Hawaii, Sep. 2024.
2.	Mako Fukumoto, Hidenori ANDO, Reon Kuramoto, Haruka Takata and Tatsuhiro Ishida : A unique immunization method to induce antibodies: intravenous administration of PEGylated exosomes with splenic uptake, CRS 2024 Annual Meeting & Exposition, Bologna, Jul. 2024.
3.	Haruka Yamamoto, Hidenori ANDO, Haruka Takata, Yasukazu Omoto and Tatsuhiro Ishida : Development of a novel human TNF-alpha vaccine formulation: Immunization with inactivated human TNF-alpha variant to induce anti-TNF-alpha antibodies, CRS 2024 Annual Meeting & Exposition, Bologna, Jul. 2024.
4.	Shoichiro Fukuda, Hidenori ANDO, Chihiro Kato, Haruka Takata, Takashi Nakae, Noboru Tatsumi, Hidetoshi Hamamoto and Tatsuhiro Ishida : Ionic liquids improve intestinal absorption of macromolecules of lower molecular weights, CRS 2024 Annual Meeting & Exposition, Bologna, Jul. 2024.
5.	Matsuo Cristina Amorim Nana, Hidenori ANDO, Haruka Takata and Tatsuhiro Ishida : Protein-bound cisplatin may increase therapeutic index for cisplatin by reducing its adverse effects, CRS 2024 Annual Meeting & Exposition, Bologna, Jul. 2024.
6.	Hidenori ANDO, Haruka Takata, Taro Shimizu and Tatsuhiro Ishida : A unique spleen-targeted antigen delivery system to obtain antigen-specific antibodies, CRS 2024 Annual Meeting & Exposition, Bologna, Jul. 2024.
7.	Haruka Takata, Shunji Abe, Hidenori ANDO and Tatsuhiro Ishida : Effect of anti-PEG IgM on the intramuscular vaccination and pharmacokinetics of mRNA/LNP, CRS 2024 Annual Meeting & Exposition, Bologna, Jul. 2024.
8.	Hitoshi Matsumoto, Haruka Takata, Hidenori ANDO and Tatsuhiro Ishida : In vivo tumor targeting by NH2-terminated PEG-modified liposomes, Liposome Research Days 2024, Glasgow, Jun. 2024.
9.	Shunji Abe, Haruka Takata, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : Effect of anti-PEG IgM on vaccine efficacy and phrmacokinetics of intramuscuraly administrated PEGylated lipid nanoparticles, Liposome Research Days 2024, Glasgow, Jun. 2024.
10.	Rina Yamade, Haruka Takata, Hidenori ANDO and Tatsuhiro Ishida : Induction of anti-PEG antibodies by PEGylated liposomes following oral administration, Liposome Research Days 2024, Glasgow, Jun. 2024.
11.	Haruka Takata, Hidenori ANDO and Tatsuhiro Ishida : Effect of administration route on the anti-PEG IgM induction by PEGylated liposomes, Liposome Research Days 2024, Glasgow, Jun. 2024.
12.	Haruka Takata, Shunji Abe, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : Impact of pre-existing anti-PEG IgM on the mRNA/LNP i.m. vaccination, 16th International Symposium on Nanomedicine, Osaka, Nov. 2023.
13.	Hitoshi Matsumoto, Haruka Takata, Ayano Sawa-Aihara, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : Investigation of therapeutic efficacy of proteasome inhibitor-encapsulated PEG-modified liposomes for UUO-induced renal fibrosis, 16th International Symposium on Nanomedicine, Osaka, Nov. 2023.
14.	Shoichiro Fukuda, Hidenori ANDO, Chihiro Kato, Haruka Takata, T Nakae, N Tatsumi, H Hamamoto and Tatsuhiro Ishida : The molecular weight limitation on increased intestinal absorption by ionic liquids, 16th International Symposium on Nanomedicine, Osaka, Nov. 2023.
15.	E Kaneko, H Tsujisaki, M Fujiwara, Hidenori ANDO, Tatsuhiro Ishida, H Tani and K Tajima : Suppression of mechanical stress in suspension culture of mammalian cells by nanofibrillated bacterial cellulose, The 5th International Cellulose Conference (ICC2022+1), Hiroshima, Sep. 2023.
16.	Hidenori ANDO : Therapeutic outcome of combination treatment with PEGylated liposomal oxaliplatin and rituximab in B-cell lymphoma-xenograft mouse model, The 9th China-Japan Joint Meeting of Basic and Clinical Pharmacology, Shanghai, Jul. 2023.
17.	Haruka Yamamoto, Hidenori ANDO, Omoto Yasukazu, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : Induction of neutralizing antibodies by immunization with inactivated human TNF-alpha in mice, 15th International Symposium on Nanomedicine, Tokushima, Dec. 2022.
18.	Shunto Yamamoto, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : Development of a novel technique for antibody induction against membrane proteins by spleen immunization with membrane protein-loaded PEG-modified liposomes, 15th International Symposium on Nanomedicine, Tokushima, Dec. 2022.
19.	Takaaki Matsuzaki, Taro Shimizu, Hidenori ANDO, Yu Ishima, K Yamanaka, H Hamamoto and Tatsuhiro Ishida : An ionic liquids-based topical antitumor vaccine: a mechanism for induction of antitumor immunity via topical application of cancer-antigen peptides, 15th International Symposium on Nanomedicine, Tokushima, Dec. 2022.
20.	Aiko Hashimoto, Yu Ishima, Hidenori ANDO, Taro Shimizu and Tatsuhiro Ishida : Differential organ-specific distribution of human serum albumin denatured by various modifications, 15th International Symposium on Nanomedicine, Tokushima, Dec. 2022.
21.	Riku Uehara, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : Neutralization of acidic tumor microenvironment by dosing of sodium potassium citrate (K/Na citrate) enhances antitumor effects of Abraxane®, 15th International Symposium on Nanomedicine, Tokushima, Dec. 2022.
22.	Shoichiro Fukuda, Hidenori ANDO, Atsuya Maruyama, Takashi Nakae, Noboru Tatsumi, Hidetoshi Hamamoto, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : The mechanism investigation of intestinal absorption enhancement of drugs using ionic liquids, 15th International Symposium on Nanomedicine, Tokushima, Dec. 2022.
23.	Eslam Mostafa Ramadan Abdelhameed, Hidenori ANDO, Haruka Yamamoto, Mako Fukumoto, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : Preparation, optimization, and evaluation of anionic DPPG-based LNPs for delivery of peptide antigens, 15th International Symposium on Nanomedicine, Tokushima, Dec. 2022.
24.	Nana Matsuo, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : Oral sodium bicarbonate enhances accumulation and antitumor effects of PEGylated liposomal doxorubicin (Doxil®), 15th International Symposium on Nanomedicine, Tokushima, Dec. 2022.
25.	Yoshino Kawaguchi, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : Transfusion of mouse B cells, embedded antigens with hydroxyl PEG-modified liposomes in vitro, induces cellular immune responses in mice, 15th International Symposium on Nanomedicine, Tokushima, Dec. 2022.
26.	A S Gaballa, Taro Shimizu, Hidenori ANDO, Yu Ishima, Sherif Abdallah Emam Emam, M Ibrahim, M F Mady, W Y Naguib, A K Khaled and Tatsuhiro Ishida : Accelerated blood clearance of PEGylated liposomal antitumor agents after topical application of PEG derivatives containing cosmetics in a mouse model, 15th International Symposium on Nanomedicine, Tokushima, Dec. 2022.
27.	Hidenori ANDO, K Tajima, T Matsushima, T Kusano and Tatsuhiro Ishida : Functions of exosomes secreted from nano-fibrillated bacterial cellulose-based 3D spheroids derived from cancer cells or mesenchymal stem cells, 15th International Symposium on Nanomedicine, Tokushima, Dec. 2022.
28.	Takeru Hirai, Nanami Tasaka, Hidenori ANDO, Taro Shimizu, Tatsuhiro Ishida and Yu Ishima : Biological roles of supersulfide in human hair, Redox Week in Sendai 2022, Sendai, Oct. 2022.
29.	Yamade Rina, Taro Shimizu, Hirakawa Naoki, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : Human serum albumin (HSA)-based nanocarriers efficiently deliver antigens to the spleen and induce antigen-specific humoral immunity, 14th International Symposium on Nanomedicine, Nov. 2021.
30.	Haruka Takata, Taro Shimizu, Ueda Hiro, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : The induction level of anti-PEG IgM by PEGylated liposomes depends on the route of administration and the presence of nucleic acids, 14th International Symposium on Nanomedicine, Nov. 2021.
31.	Hidenori ANDO, Tajima Kenji, Matsushima Tokuo, Kusano Takatomo and Tatsuhiro Ishida : Evaluation of exosomes derived from spheroids prepared by 3D cell culture system using nano-fibrillated bacterial cellulose, 14th International Symposium on Nanomedicine, Nov. 2021.
32.	Taro Shimizu, Kohga Miyahara, G Kozma, Hidenori ANDO, Yu Ishima, J Szebeni and Tatsuhiro Ishida : Pre-treatment with Doxebo suppresses anti-PEG IgM immune responses through PEG-specific immune tolerance, 17th International Symposium on Blood Substitutes & Oxygen Therapeutics, Nara, Nov. 2019.
33.	Sherif Abdallah Emam Emam, Hidenori ANDO, Taro Shimizu and Tatsuhiro Ishida : The impact of cell-type tropism on the intratumor accumulation of exosomes derived from cancer cells, Liposome Research Days 2019, Sapporo, Sep. 2019.
34.	Maho Tagami, Hidenori ANDO, Ai Ikeda, K Eshima, C.L Huang, H Wada and Tatsuhiro Ishida : Enhanced therapeutic efficacy of liposomal weak-base anticancer drugs by daily oral administration of sodium bicarbonate, Liposome Research Days 2019, Sapporo, Sep. 2019.
35.	Yuna Shimazaki, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : Immunization method to obtain antigen-specific antibodies by antigen delivery to splenic marginal zone B cells using PEGylated liposomes, Liposome Research Days 2019, Sapporo, Sep. 2019.
36.	Emam Emam Abdallah Sherif, Hidenori ANDO, Lila Selim Ahmed Ali Abu Amr, Yu Ishima, A M Mahdy, S F Ghazy and Tatsuhiro Ishida : The effect of liposome co-incubation with cancer cells on the secretion, uptake propensity and expression of certain surface proteins of cancer cell-derived exosomes (extracellular vesicles), 2018 CRS Annual Meeting & Exposition, New York, Jul. 2018.
37.	Tatsuhiro Ishida, Hidenori ANDO, M Fukushima, C.L Huang and H Wada : An industrial method of manufacturing a novel RNAi anticancer drug, DFP-10825, for the treatment of peritoneal disseminated gastric cancer, AACR Annual Meeting 2017, Washington, D.C., Apr. 2017.
38.	Nozomi Kinjoh, Hidenori ANDO, Noriko Saito-Tarashima, Noriaki Minakawa and Tatsuhiro Ishida : Targeted gene silencing by introduction of intelligent RNA expression device (iRed), Liposome Advances 2015, London, Dec. 2015.
39.	Noriko Saito-Tarashima, Kinjo Nozomi, Kojima Takamitsu, Hidenori ANDO, Tatsuhiro Ishida and Noriaki Minakawa : Gene silencing via RNA interference (RNAi) machinery using 4'-thioDNA as an artificial template, The 42nd International Symposium on Nucleic Acids Chemistry, Himeji, Sep. 2015.

Proceeding of Domestic Conference:

1.	Matsuo Cristina Amorim Nana, Hidenori ANDO, Haruka Takata and Tatsuhiro Ishida : Protein-bound cisplatin can induce therapeutic action for cisplatin with lessening its adverse events, APSTJ Global Education Seminar 2024, Oct. 2024.
2.	Matsuo Cristina Amorim Nana, Hidenori ANDO, Haruka Takata and Tatsuhiro Ishida : HPLC/ICP-MS測定系を用いたシスプラチンのタンパク結合解析とタンパク結合形シスプラチンが副作用および抗腫瘍効果に与える影響の評価, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
3.	Mei Morikawa, Shoichiro Fukuda, Hidenori ANDO, Haruka Takata, 中江崇, 辰巳昇, 濱本英利 and Tatsuhiro Ishida : イオン液体を用いた中分子化合物の経皮吸収促進技術の開発:吸収における分子量閾値の探索, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
4.	Hina Naruoka, Hidenori ANDO, Haruka Takata, Taro Shimizu and Tatsuhiro Ishida : 幼若マウスへ投与されたPEG修飾リポソームに対する免疫応答の評価:投与経路による抗PEG抗体誘導性の違い, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
5.	Yuri Kim, Haruka Takata, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : PEG誘導体含有化粧水の連日皮膚塗布で確認された抗PEG IgM誘導に対する脾臓およびT細胞の関与, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
6.	Nanako Kan, Hidenori ANDO, Matsuo Cristina Amorim Nana, Takaya Sunami, Yusuke Doi, Haruka Takata and Tatsuhiro Ishida : オキサリプラチン封入リポソームとリツキサン®の併用投与におけるヒトリンパ腫移植マウスに対する抗腫瘍効果とマクロファージの貪食活性に関する検討, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
7.	Moe Kawakami, Haruka Takata, Hidenori ANDO and Tatsuhiro Ishida : 骨髄腫同所移植モデルマウスの作製およびCOOH末端PEG修飾リポソームの集積性の検討, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
8.	Hitoshi Matsumoto, Haruka Takata, Hidenori ANDO and Tatsuhiro Ishida : アミン末端PEG修飾リポソームを用いた酸性環境標的化DDSの開発, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
9.	Mako Fukumoto, Hidenori ANDO, 松島得雄, 草野貴友, Haruka Takata and Tatsuhiro Ishida : 3D培養細胞由来エクソソームの特性及び構成タンパクの評価, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
10.	Sotaro Kudo, Hidenori ANDO, Yoshino Kawaguchi, Taro Shimizu, Haruka Takata and Tatsuhiro Ishida : 異なるPEG末端を持つmRNA搭載PEG修飾脂質ナノ粒子の脾臓免疫細胞への移行性とタンパク質発現評価, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
11.	Haruka Yamamoto, Hidenori ANDO, Haruka Takata, 大本安一 and Tatsuhiro Ishida : 生体内で抗PD-1抗体を誘導するPD-1ペプチドワクチンの開発の基礎的検討:免疫後の抗体誘導評価と抗腫瘍効果, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
12.	Kenta Mizumachi, Taro Shimizu, Yoshino Kawaguchi, Haruka Takata, Hidenori ANDO and Tatsuhiro Ishida : 脾臓辺縁帯B細胞標的化リポソームをSLEモデルマウス・MRL/lprマウスに投与した際の標的化能力低下の原因究明, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
13.	Shunji Abe, Haruka Takata, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : mRNA搭載脂質ナノ粒子に修飾されたPEGに対する免疫応答に脾臓および胸腺が与える影響, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
14.	Shoichiro Fukuda, Haruka Takata, 中江崇, 辰巳昇, 濱本英利, Hidenori ANDO and Tatsuhiro Ishida : イオン液体による中分子化合物の経口吸収促進機構の解明;消化管密着結合及び消化管吸収部位への影響, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
15.	Hitoshi Matsumoto, Haruka Takata, Hidenori ANDO and Tatsuhiro Ishida : Acidic environment targeting by NH2-terminated PEG-modified liposomes, 2024 Tokushima Bioscience Retreat, Sep. 2024.
16.	Shoichiro Fukuda, Haruka Takata, Takashi Nakae, Noboru Tatsumi, Hidetoshi Hamamoto, Hidenori ANDO and Tatsuhiro Ishida : Ionic liquids improve intestine absorption of macromolecules, 2024 Tokushima Bioscience Retreat, Sep. 2024.
17.	Matsuo Cristina Amorim Nana, Hidenori ANDO, Haruka Takata and Tatsuhiro Ishida : Protein-bound form of cisplatin may potentiate therapeutic outcome of cisplatin treatment via minimizing its adverse effects, 2024 Tokushima Bioscience Retreat, Sep. 2024.
18.	Kan Nanako, Hidenori ANDO, Matsuo Nana, Sunami Takaya, Doi Yusuke, Haruka Takata and Tatsuhiro Ishida : ヒトリンパ腫移植マウスにおけるオキサリプラチン封入PEG修飾リポソームとリツキサン併用時における抗腫瘍効果の検討:マクロファージの寄与, 第32回DDSカンファランス, Sep. 2024.
19.	Naruoka Hina, Hidenori ANDO, Haruka Takata, Taro Shimizu and Tatsuhiro Ishida : 幼若マウスに腹腔内投与されたPEG修飾リポソームの抗PEG抗体誘導性と脾臓集積性の評価, 第32回DDSカンファランス, Sep. 2024.
20.	Kudo Sotaro, Hidenori ANDO, Kawaguchi Yoshino, Taro Shimizu, Haruka Takata and Tatsuhiro Ishida : 脾臓送達技術を用いて投与したmRNA搭載PEG修飾脂質ナノ粒子の脾臓免疫細胞への移行性とタンパク質発現評価, 第29回創剤フォーラム若手研究会, Sep. 2024.
21.	Shunji Abe, Haruka Takata, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : PEG修飾脂質ナノ粒子の筋肉内投与による抗PEG抗体誘導への脾臓及びT細胞の寄与, 日本核酸医薬学会第9回年会, Jul. 2024.
22.	Tatsuhiro Ishida, Taro Shimizu, Fukuda Shoichiro, Haruka Takata and Hidenori ANDO : イオン液体を用いた中分子化合物の吸収促進技術の開発, 第40回日本DDS学会学術集会, Jul. 2024.
23.	Hidenori ANDO, Haruka Takata, Taro Shimizu and Tatsuhiro Ishida : Induction of antigen-specific antibodies by a unique antigen delivery system targeting to spleen, 第40回日本DDS学会学術集会, Jul. 2024.
24.	Shunji Abe, Haruka Takata, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : Impact of ant-PEG IgM on in vivo performance of PEGylated mRNA/LNP via intramuscularly injection, 第40回日本DDS学会学術集会, Jul. 2024.
25.	Haruka Takata, Shunji Abe, Hidenori ANDO and Tatsuhiro Ishida : Effect of administration route on the anti-PEG IgM induction by PEGylated nanoparticles, 第40回日本DDS学会学術集会, Jul. 2024.
26.	Mizumachi Kenta, Kawaguchi Yoshino, Haruka Takata, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : 全身性エリテマトーデス(SLE)治療を目指した脾臓辺縁帯B細胞標的化リポソーム開発におけるMRL/lprマウスモデル使用時の課題, 第40回日本DDS学会学術集会, Jul. 2024.
27.	Matsumoto Hitoshi, Haruka Takata, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : PEG修飾リポソームを用いた新たな腫瘍ターゲティング戦略, 第40回日本DDS学会学術集会, Jul. 2024.
28.	Kim Yuri, Haruka Takata, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : PEG誘導体含有化粧水の連日皮膚塗布で確認された抗PEG IgM誘導に対する脾臓およびT細胞の関与, 第40回日本DDS学会学術集会, Jul. 2024.
29.	Matsuo Nana, Hidenori ANDO, 田島健次, Haruka Takata, 松島得雄, 草野貴友 and Tatsuhiro Ishida : 細菌由来ナノセルロースの経口摂取による腸内細菌叢調節が食事性肥満モデルマウスの体重増加に与える影響の評価, 第78回日本栄養・食糧学会大会, May 2024.
30.	Matsuo Nana, Hidenori ANDO, Haruka Takata and Tatsuhiro Ishida : 白金製剤シスプラチンのタンパク結合形が副作用と抗腫瘍効果に与える影響の評価, 日本薬剤学会第39年会, May 2024.
31.	Fukuda Shoichiro, Kato Chihiro, Haruka Takata, 中江崇, 辰巳昇, 濱本英利, Hidenori ANDO and Tatsuhiro Ishida : イオン液体による中分子化合物の経口吸収促進機構の解明に関する検討;消化管上皮タイトジャンクションと化合物の消化管内滞留性への影響, 日本薬剤学会第39年会, May 2024.
32.	Kan Nanako, Hidenori ANDO, Matsuo Nana, Sunami Takaya, Doi Yusuke, Haruka Takata, Masahiro Abe and Tatsuhiro Ishida : ヒト悪性リンパ腫細胞の異種移植モデルに対するオキサリプラチン封入リポソームの単独あるいは抗体医薬との併用における抗腫瘍効果の検討, 日本薬剤学会第39年会, May 2024.
33.	Kim Yuri, Haruka Takata, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : 化粧水塗布による抗PEG IgM誘導メカニズムに関する検討:脾臓およびT細胞の関与, 日本薬剤学会第39年会, May 2024.
34.	Naruoka Hina, Hidenori ANDO, Haruka Takata, Taro Shimizu and Tatsuhiro Ishida : 幼若マウスに対するPEG修飾リポソームの投与による抗PEG抗体誘導の評価, 日本薬剤学会第39年会, May 2024.
35.	Hara Yuto, Hidenori ANDO, Haruka Yamamoto, Haruka Takata, 大本安一 and Tatsuhiro Ishida : キャリアフリーでhTNFαペプチドを免疫して誘導した抗hTNFα抗体の評価と動物種間(マウス・ウサギ)での抗体誘導の比較, 日本薬剤学会第39年会, May 2024.
36.	Haruka Takata, Shunji Abe, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : ポリエチレングリコール(PEG)に対する抗体が及ぼすCOVID-19 mRNAワクチン筋肉内投与後のタンパク質翻訳への影響, 日本薬学会第144年会, Mar. 2024.
37.	Yoshino Kawaguchi, Taro Shimizu, Haruka Takata, Hidenori ANDO and Tatsuhiro Ishida : B細胞は補体結合リポソームを他の抗原提示細胞へ受け渡す, 日本薬学会第144年会, Mar. 2024.
38.	Mako Fukumoto, Hidenori ANDO, 松島得雄, 草野貴友, Haruka Takata and Tatsuhiro Ishida : 細菌由来ナノセルロースを3D培養基材として用いて調製したエクソソームの有用性検討;エクソソームの分泌特性とタンパク発現の評価, 日本薬学会第144年会, Mar. 2024.
39.	Haruka Yamamoto, Hidenori ANDO, Haruka Takata, 大本安一 and Tatsuhiro Ishida : 生体内で抗PD-1抗体を誘導するPD-1ペプチドワクチン開発の基礎的検討:免疫後の抗血清を用いた結合性評価, 日本薬学会第144年会, Mar. 2024.
40.	Yuri Deai, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : 脾臓辺縁帯B細胞を標的としたがんペプチドワクチンと化学療法剤の併用による抗腫瘍効果誘導に関する検討, 日本薬学会第144年会, Mar. 2024.
41.	Nana Matsuo, Hidenori ANDO, Haruka Takata and Tatsuhiro Ishida : CDDPのタンパク結合率制御による副作用軽減と治療効果増強に関する研究:遊離型またはタンパク結合型CDDPが腎臓に与える副作用の評価, 日本薬学会第144年会, Mar. 2024.
42.	Rina Yamade, Haruka Takata, Hidenori ANDO and Tatsuhiro Ishida : 抗PEG抗体誘導にPEG修飾リポソームの投与経路が及ぼす影響, 日本薬学会第144年会, Mar. 2024.
43.	Haruka Yamamoto, Hidenori ANDO, Haruka Takata, 大本安一 and Tatsuhiro Ishida : 新規hTNFαワクチン製剤の開発を目指した不活化hTNFα誘導体のマウスへの免疫と抗体誘導評価, 第2回日本抗体学会学術大会, Dec. 2023.
44.	Mako Fukumoto, Hidenori ANDO, Reon Kuramoto, Haruka Takata and Tatsuhiro Ishida : エクソソームの脾臓免疫による抗体誘導評価:ホスト細胞膜表面に対する結合性評価, 第2回日本抗体学会学術大会, Dec. 2023.
45.	Haruka Takata, Shunji Abe, Hidenori ANDO and Tatsuhiro Ishida : mRNA/LNPによるタンパク翻訳へ抗PEG IgMが及ぼす影響, 第10回DDS製剤臨床応用FG合宿討論会, Nov. 2023.
46.	Masaki Takata, Hidenori ANDO, 田島健次, 松島得雄, 草野貴友, Chikako Asada, Yoshitoshi Nakamura and Tatsuhiro Ishida : 物性の異なるナノセルロースを用いて調製したパクリタキセル包埋CNFの調製∼腹膜播種モデルマウスでの抗腫瘍効果の検討∼, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2023.
47.	Aiko Hashimoto, Yu Ishima, Hidenori ANDO and Tatsuhiro Ishida : アルブミンを基盤とした臓器特異的移行性を有するDDSキャリアの作製, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2023.
48.	Deai Yuri, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : 脾臓辺縁帯B細胞を標的としたがんペプチドワクチンによる抗腫瘍効果誘導に関する検討, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2023.
49.	Yoshino Kawaguchi, Taro Shimizu, Haruka Takata, Hidenori ANDO and Tatsuhiro Ishida : 補体結合リポソームによる抗原搭載法を利用した新規B細胞ワクチンの開発, 第27回日本ワクチン学会・第64回日本臨床ウイルス学会合同学術集会, Oct. 2023.
50.	Fukuda Shoichiro, Hidenori ANDO, Chihiro Kato, Haruka Takata, 中江崇, 辰巳昇, 濱本英利 and Tatsuhiro Ishida : イオン液体を新規吸収促進剤として用いた中分子化合物の経口吸収改善効果に関する検討, 第44回生体膜と薬物の相互作用シンポジウム, Oct. 2023.
51.	Shunto Yamamoto, Hidenori ANDO, Taro Shimizu, Haruka Takata and Tatsuhiro Ishida : 膜タンパク質搭載PEG修飾リポソームの脾臓辺縁帯領域から濾胞領域への送達による膜タンパク質に対する抗体誘導, 第44回生体膜と薬物の相互作用シンポジウム, Oct. 2023.
52.	Fukuda Shoichiro, Hidenori ANDO, Chihiro Kato, Haruka Takata, Takashi Nakae, Noboru Tatsumi, Hidetoshi Hamamoto and Tatsuhiro Ishida : The molecular weight limitation on increased intestinal absorption by ionic liquids, 日本薬物動態学会第38回年会, Sep. 2023.
53.	金子瑛一郎, 辻崎晴人, 藤原政司, Hidenori ANDO, Tatsuhiro Ishida, 谷博文 and 田島健次 : ナノフィブリル化バクテリアセルロースを用いた浮遊細胞培養における機械的ストレスの低減, セルロース学会第30回年次大会, Sep. 2023.
54.	Nana Matsuo, Hidenori ANDO, 田島健次, 松島得雄, 草野貴友 and Tatsuhiro Ishida : 細菌由来ナノセルロースを用いたHepG2肝がんスフェロイドの作製検討と薬物代謝活性評価, セルロース学会第30回年次大会, Sep. 2023.
55.	Hidenori ANDO : Preparation of hepatic cancer spheroids using bacterial nano-cellulose and evaluation of its drug-metabolism activity for accelerating drug discovery, 日本薬物動態学会第38回年会, Sep. 2023.
56.	Hidenori ANDO : 脾臓標的DDS技術を利用した脾臓免疫による抗体誘導評価, 徳島大学大学院医歯薬学研究部DDS研究センター・徳島大学研究クラスター「次世代DDS拠点形成/1q増幅がもたらす腫瘍の進展・難治性病態の解明とその克服のための新規治療薬の創出」・SDGs推進に係る連携創出の場形成支援事業合同シンポジウム, Sep. 2023.
57.	金子瑛一郎, 辻崎晴人, 藤原政司, Hidenori ANDO, Tatsuhiro Ishida, 谷博文 and 田島健次 : ナノフィブリル化バクテリアセルロースを用いたCHO細胞の浮遊培養における細胞死の抑制と抗体生産性への影響, 第75回日本生物工学会大会, Sep. 2023.
58.	Hidenori ANDO : 疾病治療を目指したNFBC の医用基材としての応用研究, 第15回ロバスト農林水産工学「科学技術先導研究会」, Aug. 2023.
59.	Shunji Abe, Haruka Takata, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : 筋注後筋組織から血中に漏出した脂質ナノ粒子(LNP)の体内動態に抗PEG IgMが与える影響, 遺伝子・デリバリー研究会第21回夏期セミナー, Aug. 2023.
60.	Tatsuhiro Ishida, Sherif Armia, Taro Shimizu, Hidenori ANDO and Yu Ishima : 化粧水の塗布による抗PEG IgMの誘導が抗がん剤封入PEG修飾リポソームの抗腫瘍効果に与える影響, 第39回日本DDS学会学術集会, Jul. 2023.
61.	Tanaka Haruki, Hidenori ANDO, Shunto Yamamoto, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : がん細胞由来膜タンパク質を搭載したPEG修飾リポソームを脾臓に送達する技術を利用したがんワクチンの開発:細胞性免疫誘導の評価, 第39回日本DDS学会学術集会, Jul. 2023.
62.	Kudoh Sohtaroh, Hidenori ANDO, Yoshino Kawaguchi, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 末端構造の異なるPEG修飾リポソームの単独あるいは繰り返し投与における脾臓免疫細胞への移行性評価, 第39回日本DDS学会学術集会, Jul. 2023.
63.	Fukumoto Mako, Hidenori ANDO, Sherif Abdallah Emam Emam, Nana Matsuo, 松島得雄, 草野貴友, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : NFBCを新規培養基材として用いた3D培養の有用性に関する研究:得られたエクソソームの細胞増殖と細胞内取り込みに与える影響の評価, 第39回日本DDS学会学術集会, Jul. 2023.
64.	Shunto Yamamoto, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : がん細胞由来膜タンパク質を搭載したPEG修飾リポソームを脾臓に送達する技術を利用したがんワクチンの開発:腫瘍増殖抑制効果の評価, 第39回日本DDS学会学術集会, Jul. 2023.
65.	Rina Yamade, Haruka Takata, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : PEG修飾リポソームの経口投与による抗PEG抗体誘導メカニズムに関する基礎的検討, 第39回日本DDS学会学術集会, Jul. 2023.
66.	Riku Uehara, Hidenori ANDO, Taro Shimizu, Yu Ishima, 江島清 and Tatsuhiro Ishida : アルカリ化剤の経口投与による腫瘍酸性環境改善とアブラキサン®の併用による抗腫瘍効果増強, 第39回日本DDS学会学術集会, Jul. 2023.
67.	Fukuda Shoichiro, Hidenori ANDO, 中江崇, 辰巳昇, 濱本英利, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : イオン液体による難吸収性中分子化合物の腸管吸収促進効果の検討, 第39回日本DDS学会学術集会, Jul. 2023.
68.	Naoto Okada, Taro Shimizu, Hidenori ANDO, Tatsuhiro Ishida, Keisuke Ishizawa and 北原隆志 : 血液腫瘍患者における抗PEG抗体価の定量評価によるPEG修飾G-CSF関連有害事象の予測, 医療薬学フォーラム2023 / 第31回クリニカルファーマシーシンポジウム, Jul. 2023.
69.	Hidenori ANDO : 腹膜播種治療を目指した臨床応用可能な腹腔内投与型核酸医薬製剤の開発, 日本薬剤学会第38年会, May 2023.
70.	Haruka Takata, Taro Shimizu, Shunji Abe, Hidenori ANDO and Tatsuhiro Ishida : デキサメタゾンの事前投与によるmRNA封入PEG修飾脂質ナノ粒子投与時の抗PEG抗体誘導抑制に関する検討, 日本薬剤学会第38年会, May 2023.
71.	Mohamed Ibrahim, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 化粧水塗布時の含有PEGの皮膚透過と抗PEG IgM誘導に関する検討, 日本薬剤学会第38年会, May 2023.
72.	Shunto Yamamoto, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 膜タンパク質搭載PEG修飾リポソームの脾臓送達による各種がん細胞上の膜タンパク質に対する抗体誘導, 日本薬剤学会第38年会, May 2023.
73.	Haruka Yamamoto, Hidenori ANDO, 大本安一, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 抗ヒトTNFα抗体の生体内誘導を実現するTNFα由来ペプチドの免疫と抗体誘導評価, 日本薬剤学会第38年会, May 2023.
74.	Fukumoto Mako, Hidenori ANDO, Sherif Abdallah Emam Emam, Nana Matsuo, 松島得雄, 草野貴友, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : NFBCを新規培養基材として用いた3D培養の有用性に関する研究:培養時のエクソソーム分泌性と得られたエクソソームの細胞増殖等に与える影響の評価, 日本薬剤学会第38年会, May 2023.
75.	Nana Matsuo, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : HPLCとICP-MSを組み合わせたオキサリプラチン遊離型とタンパク結合型の分離評価法の確立, 日本薬剤学会第38年会, May 2023.
76.	Fukuda Shoichiro, Hidenori ANDO, Maruyama Atsuya, 中江崇, 辰巳昇, 濱本英利, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : イオン液体を基剤とした難吸収性中分子化合物の腸管吸収改善の検討, 日本薬剤学会第38年会, May 2023.
77.	Yoshino Kawaguchi, Hidenori ANDO, Nana Matsuo, 田島健次, 長澤一樹, 松島得雄, 草野貴友 and Tatsuhiro Ishida : ナノフィブリル化バクテリアセルロースの経口摂取がもたらす腸内細菌叢の多様性変動と食事性肥満の改善, 第77回日本栄養・食糧学会大会, May 2023.
78.	Takeru Hirai, Hiroki Osafune, Taro Shimizu, Hidenori ANDO, Tatsuhiro Ishida and Yu Ishima : 免疫グロブリン中に含まれる超硫黄分子の検出とその機能解明, 日本薬学会第143年会, Mar. 2023.
79.	Rina Yamade, Taro Shimizu, Naoki Hirakawa, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : モデル抗原搭載アルブミンナノ粒子とアジュバントの併用によるがん治療効果検討, 日本薬学会第143年会, Mar. 2023.
80.	Yuki Matsugi, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : ドキソルビシン封入リポソーム搭載脾臓細胞による抗腫瘍効果の検討, 日本薬学会第143年会, Mar. 2023.
81.	Yoshino Kawaguchi, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : B細胞に搭載されたヒドロキシ末端PEG修飾リポソームは補体受容体を介して他の抗原提示細胞へと受け渡される, 日本薬学会第143年会, Mar. 2023.
82.	Terutsugu Tanizawa, Mai Inagaki, Hidetaka Kosako, Hidenori ANDO, Tatsuhiro Ishida and Masanori Tachikawa : 抗ヒト脳微小血管内皮細胞抗体の標的受容体の探索, 日本薬学会第143年会, Mar. 2023.
83.	Haruka Yamamoto, Hidenori ANDO, 大本安一, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 抗hTNFα抗体を生体内で誘導するhTNFαペプチド配列の探索と抗体誘導評価, 日本薬学会第143年会, Mar. 2023.
84.	Takaya Sunami, Hidenori ANDO, Yusuke Doi, Taro Shimizu, Yu Ishima, 安倍正博 and Tatsuhiro Ishida : 悪性リンパ腫に対するオキサリプラチン封入PEG修飾リポソームと抗体医薬の併用による抗腫瘍効果の検討, 日本薬学会第143年会, Mar. 2023.
85.	Rina Yamade, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : Investigation of the usefulness of human serum albumin nanoparticles as antigen delivery carriers to the spleen, 日本薬剤学会第2回英語セミナー, Feb. 2023.
86.	Haruka Yamamoto, Hidenori ANDO, 大本安一, Yoshino Kawaguchi, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 不活化ヒト TNFα 誘導体のマウスへの免疫による中和抗体の誘導評価, 第1回日本抗体学会設立記念学術大会, Nov. 2022.
87.	Nana Matsuo, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 白金製剤と血漿タンパク質との相互作用:時間依存性に関する検討, 日本薬物動態学会第37回年会, Nov. 2022.
88.	Kenta Mizumachi, Taro Shimizu, Hiro Ueda, Haruka Takata, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 全身性エリテマトーデスモデルマウス由来B細胞の取り込み能についての検討, 第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2022.
89.	Haruka Yamamoto, Hidenori ANDO, 大本安一, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : Humira®(adalimumab)投与時の抗薬物抗体(ADA)誘導に関する検討:マウス型抗ヒトTNFαモノクローナル抗体をマウスに投与した際のADA誘導, 第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2022.
90.	Haruka Takata, Taro Shimizu, Shunji Abe, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : デキサメタゾンが及ぼすPEG修飾ナノ粒子による抗PEG抗体誘導への影響, 第16回次世代を担う若手医療薬科学シンポジウム, Oct. 2022.
91.	Shunto Yamamoto, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 膜タンパク質搭載PEG修飾リポソームの脾臓送達による抗膜タンパク質抗体誘導, 第43回生体膜と薬物の相互作用シンポジウム, Oct. 2022.
92.	Haruka Takata, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : PEG修飾リポソームの投与経路がおよぼす抗PEG抗体誘導への影響に関する検討, 第43回生体膜と薬物の相互作用シンポジウム, Oct. 2022.
93.	Naoto Okada, Shingen Nakamura, Taro Shimizu, Hidenori ANDO, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Mitsuhiro Goda, Tatsuhiro Ishida and Keisuke Ishizawa : 免疫不全リスクを有する患者における新型コロナワクチンによる抗体獲得能に関連する因子の検討, 第32回日本医療薬学学会, Sep. 2022.
94.	Takaya Sunami, Hidenori ANDO, Yusuke Doi, Taro Shimizu, Yu Ishima, Masahiro Abe and Tatsuhiro Ishida : オキサリプラチン封入PEG修飾リポソームの悪性リンパ腫治療への展開, 第27回創剤フォーラム若手研究会, Sep. 2022.
95.	Shoichiro Fukuda, Hidenori ANDO, Atsuya Maruyama, 中江崇, 辰巳昇, 濱本英利, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : イオン液体による薬物の腸管吸収促進メカニズムの検討, 第27回創剤フォーラム若手研究会, Sep. 2022.
96.	Nana Matsuo, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 重曹の経口投与によるDoxil®の腫瘍集積性向上と抗腫瘍効果増強, 第27回創剤フォーラム若手研究会, Sep. 2022.
97.	Ryuto Nakano, Naoki Hirakawa, Hidenori ANDO, Taro Shimizu, Tatsuhiro Ishida and Yu Ishima : 難水溶性薬物に対する溶解補助及び動態改善を企図した新規アルブミンナノ粒子の有用性評価, 日本薬剤学会第3回超分子薬剤学FGシンポジウム, Sep. 2022.
98.	Yoshino Kawaguchi, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : B細胞に標的化されたヒドロキシ末端PEG修飾リポソームは補体受容体を介して他の免疫細胞へと受け渡される, 日本薬剤学会第3回超分子薬剤学FGシンポジウム, Sep. 2022.
99.	Naoto Okada, Shingen Nakamura, Taro Shimizu, Hidenori ANDO, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Mitsuhiro Goda, Tatsuhiro Ishida and Keisuke Ishizawa : 免疫不全リスクを有する患者における新型コロナワクチンによる抗体獲得能に影響を与える因子の検討, 第32回日本医療薬学会年会, Sep. 2022.
100.	Takeru Hirai, Taro Shimizu, Hidenori ANDO, Tatsuhiro Ishida and Yu Ishima : 毛髪中に含まれる超硫黄分子の検出および機能解明, フォーラム2022:衛生薬学・環境トキシコロジー, Aug. 2022.
101.	Shunji Abe, Haruka Takata, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 血中の抗PEG抗体が筋肉内投与後のmRNA搭載LNPのタンパク質発現に与える影響に関する検討, 遺伝子・デリバリー研究会第20回夏期セミナー, Aug. 2022.
102.	Haruka Takata, Taro Shimizu, Hiro Ueda, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : siRNA搭載PEG修飾リポソームの投与経路がおよぼす抗PEG抗体誘導への影響に関する検討, 遺伝子・デリバリー研究会第20回夏期セミナー, Aug. 2022.
103.	Shunji Abe, Haruka Takata, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : mRNA搭載LNP構成成分のPEG脂質が示す免疫原性及びアナフィラキシー様反応への影響, 日本核酸医薬学会第7回年会, Aug. 2022.
104.	Ueda Hiro, Taro Shimizu, Hidenori ANDO, Yu Ishima, 山吉麻子 and Tatsuhiro Ishida : 核酸搭載リポソームの物理化学的性質が抗核酸抗体の誘導に与える影響の検討, 日本核酸医薬学会第7回年会, Aug. 2022.
105.	Yoshino Kawaguchi, Hidenori ANDO, 田島健次, 長澤一樹, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : ナノフィブリル化バクテリアセルロースの経口摂取による腸内細菌叢の変動と肥満抑制効果の評価, セルロース学会第29回年次大会, Jul. 2022.
106.	Haruka Takata, Hidenori ANDO, 田島健次, Taro Shimizu, Yu Ishima, 松島得雄, 草野貴友 and Tatsuhiro Ishida : ナノフィブリル化バクテリアセルロースを懸濁剤として用いたシクロスポリンA製剤の調製と乾癬治療効果の評価, セルロース学会第29回年次大会, Jul. 2022.
107.	Takeru Hirai, Nanami Tasaka, Taro Shimizu, Hidenori ANDO, Tatsuhiro Ishida and Yu Ishima : 毛髪中に含まれる超硫黄分子の検出および機能解明, 第49回日本毒性学会学術年会, Jul. 2022.
108.	Yukina Tottori, Naoki Hirakawa, Ryo Kinoshita, Taro Shimizu, Hidenori ANDO, Tatsuhiro Ishida and Yu Ishima : スルホサリチル酸を用いた新規アルブミンナノ粒子化法の開発と敗血症への応用, 第49回日本毒性学会学術年会, Jul. 2022.
109.	Aina Mukai, Taro Shimizu, Hidenori ANDO, Tatsuhiro Ishida and Yu Ishima : 致死性エンドトキシンショックに対するヒト血清アルブミンの治療効果の機序, 第49回日本毒性学会学術年会, Jul. 2022.
110.	Reina Hashimoto, Taro Shimizu, Hidenori ANDO, Tatsuhiro Ishida and Yu Ishima : 皮膚角質層に含まれる超硫黄分子の検出, 第49回日本毒性学会学術年会, Jul. 2022.
111.	Hidenori ANDO : 脾臓標的DDS技術を利用して刷新的な抗体を誘導する新規免疫技術の開発, 第38回日本DDS学会学術集会, Jun. 2022.
112.	Reon Kuramoto, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 緑色蛍光タンパク質(EGFP)をモデル抗原として封入したPEG修飾エクソソームの脾臓送達による抗原特異的抗体の誘導, 第38回日本DDS学会学術集会, Jun. 2022.
113.	Takaya Sunami, Hidenori ANDO, Taro Shimizu, Yu Ishima, Masahiro Abe and Tatsuhiro Ishida : オキサリプラチン封入PEG修飾リポソームの悪性リンパ腫に対する治療効果の検討, 第38回日本DDS学会学術集会, Jun. 2022.
114.	Aiko Hashimoto, Yu Ishima, Hidenori ANDO, Taro Shimizu and Tatsuhiro Ishida : アルブミンを基盤とした臓器特異的移行性を有するDDSキャリアの作製, 第38回日本DDS学会学術集会, Jun. 2022.
115.	Rina Yamade, Taro Shimizu, Naoki Hirakawa, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : ヒト血清アルブミンナノ粒子(HSAnp)を利用したDDSの新規開発とがんワクチンへの展開, 第38回日本DDS学会学術集会, Jun. 2022.
116.	Haruka Yamamoto, Hidenori ANDO, 大本安一, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 抗TNFαモノクローナル抗体(Humira)をマウスに投与した際の抗薬物抗体の誘導評価, 第38回日本DDS学会学術集会, Jun. 2022.
117.	Shunto Yamamoto, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 抗原とオボアルブミンを共封入したPEG修飾リポソームの脾臓送達による抗原特異的抗体誘導の増強効果, 第38回日本DDS学会学術集会, Jun. 2022.
118.	Haruka Takata, Milad Qelliny, Taro Shimizu, Ueda Hiro, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : ガングリオシドを用いた抗核酸抗体誘導抑制効果の検討, 日本薬剤学会第37年会, May 2022.
119.	Shunji Abe, Haruka Takata, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : mRNA封入脂質ナノ粒子構成成分のPEGに対する抗PEG抗体の誘導及びアナフィラキシー様反応への影響, 日本薬剤学会第37年会, May 2022.
120.	Shunto Yamamoto, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 抗原封入PEG修飾リポソームを利用した抗体誘導におけるOVAのアジュバント効果の検証, 日本薬剤学会第37年会, May 2022.
121.	Shunto Yamamoto, Hidenori ANDO, 冨田康治, 前田典之, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 末端構造の異なるPEGで作製した抗原封入リポソームの静脈内投与による抗体誘導に関わる免疫細胞の評価, 日本薬学会第142年会, Mar. 2022.
122.	Takaaki Matsuzaki, Taro Shimizu, Hidenori ANDO, Yu Ishima, 山中勝弘, 三輪泰司, 濱本英利 and Tatsuhiro Ishida : イオン液体を用いた経皮吸収ワクチンによる皮膚およびリンパ節における免疫細胞の活性化評価, 日本薬学会第142年会, Mar. 2022.
123.	Yoshino Kawaguchi, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 脾臓中B細胞は補体受容体介在性に捕捉した抗原キャリアを他の抗原提示細胞へ輸送する, 日本薬学会第142年会, Mar. 2022.
124.	Taro Shimizu, Sesshu Yamaguchi, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 新型コロナウイルスに対する効率的な抗体誘導を目指した脾臓辺縁帯B細胞標的化ワクチン開発に関する検討, 日本薬学会第142年会, Mar. 2022.
125.	shota fujimoto, Naoki Muguruma, Michiyasu Nakao, Hidenori ANDO, takanori miyake, 樫原孝典, Tatsuhiro Ishida, Shigeki Sano and Tetsuji Takayama : 消化管間質腫瘍(GIST)に対する新たな内視鏡診断法の確立に向けた蛍光分子イメージング技術の開発, 第18回日本消化管学会学術集会, Feb. 2022.
126.	Shunto Yamamoto, Hidenori ANDO, 前田典之, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 抗原封入リポソームの脾臓免疫による抗体誘導に関するPEG末端構造の影響, 第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2021.
127.	Masaki Takata, Hidenori ANDO, Shunsuke Akagi, 田島健次, 松島得雄, 草野貴友, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 表面物性の異なるナノフィブリル化バクテリアセルロースを用いたパクリタキセル製剤の開発と腹膜播種治療評価, 第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2021.
128.	Riku Uehara, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 重曹経口投与による腫瘍内微小環境中性化にともなう遺伝子発現解析, 第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2021.
129.	Nana Matsuo, Yu Ishima, Hidenori ANDO, Taro Shimizu and Tatsuhiro Ishida : Sulfane sulfur付加型HSAを用いた還元ストレス誘導を介するがん治療戦略, 第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2021.
130.	Taro Shimizu, Qelliny Milad, Haruka Takata, UEDA Hiro, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 核酸搭載PEG修飾カチオン性リポソームによる抗PEG抗体および抗核酸抗体誘導に及ぼすガングリオシド修飾の影響, 第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2021.
131.	Aiko Hashimoto, Yu Ishima, Hidenori ANDO, Taro Shimizu and Tatsuhiro Ishida : アルブミンを基盤とした臓器特異的移行性を有するDDSキャリアの作製, 第15回次世代を担う若手のための医療薬科学シンポジウム, Oct. 2021.
132.	茂木啓佑, 平尾彩香, 阿部礼奈, 森戸克弥, 髙山健太郎, Yusuke Doi, Hidenori ANDO, Tatsuhiro Ishida and 長澤一樹 : PEG修飾リポソーム製剤化oxaliplatin投与ラットにおいて甘味感受性の低下を誘発するその舌組織への蓄積に対する口腔冷却の影響, 第31回日本医療薬学会年会, Oct. 2021.
133.	Hidenori ANDO, Shunsuke Akagi, 田島健次, Taro Shimizu, Yu Ishima, 松島得雄, 草野貴友 and Tatsuhiro Ishida : ナノフィブリル化バクテリアセルロース(NFBC)を利用した3次元細胞培養に関する基礎的検討, セルロース学会第28回年次大会, Sep. 2021.
134.	Shunsuke Akagi, Hidenori ANDO, 田島健次, 松島得雄, 草野貴友, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : ナノフィブリル化バクテリアセルロース(NFBC)を用いた3次元培養によるヒト肝がんHepG2細胞の機能変動評価, セルロース学会第28回年次大会, Sep. 2021.
135.	Rina Yamade, Naoki Hirakawa, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 高い抗体産生誘導能を有する抗原搭載アルブミンナノ粒子の開発, 日本薬剤学会第2回超分子薬剤学FGシンポジウム, Sep. 2021.
136.	Yoshino Kawaguchi, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : Enhancement of the anti-tumor effect of B cell-based vaccines via increasing the loading amount of antigens by utilizing novel antigen carrier system, 2021 Tokushima Bioscience Retreat, Sep. 2021.
137.	Nana Matsuo, Yu Ishima, Hidenori ANDO, Taro Shimizu and Tatsuhiro Ishida : 活性イオウ付加型ヒト血清アルブミンの腫瘍への送達は小疱形成を介した細胞死を誘導する, 第29回DDSカンファランス, Sep. 2021.
138.	Hidenori ANDO, Sesshu Yamaguchi, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 新規脾臓免疫で誘導した抗体の多様性および結合性の評価, 第37回日本DDS学会学術集会, Jun. 2021.
139.	Taro Shimizu, Yuna Shimazaki, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 脾臓辺縁帯B細胞を標的としたペプチド封入リポソームによる免疫誘導に関する検討, 第37回日本DDS学会学術集会, Jun. 2021.
140.	Haruka Takata, Taro Shimizu, Yoshino Kawaguchi, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 投与経路が及ぼすPEG修飾リポソーム投与時の抗PEG抗体誘導に与える影響に関する検討, 第37回日本DDS学会学術集会, Jun. 2021.
141.	Chika Sakamoto, Taro Shimizu, Hidenori ANDO, Yu Ishima, 小林勝則, 石橋賢樹, 三輪泰司, 濱本英利 and Tatsuhiro Ishida : イオン液体を用いたIL-23 特異的siRNAの経皮送達はイミキモド誘発乾癬モデルマウスの皮膚症状を改善する, 日本核酸医薬学会第6回年会, Jun. 2021.
142.	Haruka Takata, Milad Reda Qelliny, Taro Shimizu, UEDA Hiro, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : ガングリオシドによるDNA搭載PEG修飾カチオン性リポソーム投与時のPEG及びDNAに対する抗体の産生への影響の検討, 日本核酸医薬学会第6回年会サテライト若手シンポジウム, Jun. 2021.
143.	Hidenori ANDO and Tatsuhiro Ishida : 実用性の高い腹腔内投与型核酸製剤の開発と腹膜播種治療評価, 日本核酸医薬学会第6回年会サテライト若手シンポジウム, Jun. 2021.
144.	Aiko Hashimoto, Maichi Hama, Yu Ishima, Hidenori ANDO, Taro Shimizu and Tatsuhiro Ishida : 様々なヒト血清アルブミン受容体を介した薬物キャリアの開発, 日本薬剤学会第36年会, May 2021.
145.	Aina Mukai, Yu Ishima, Hidenori ANDO, Taro Shimizu and Tatsuhiro Ishida : 致死性エンドトキシンショックに対するヒト血清アルブミンの治療効果の機序解明, 日本薬剤学会第36年会, May 2021.
146.	Reina Hashimoto, Yu Ishima, Hidenori ANDO, Taro Shimizu and Tatsuhiro Ishida : 紫外線による皮膚角質中に含まれる活性イオウ分子種の変動, 日本薬剤学会第36年会, May 2021.
147.	Takaya Sunami, Hidenori ANDO, 中江崇, 三輪泰司, 辰巳昇, 濱本英利, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : イオン液体を基剤としたLixisenatide製剤の開発と腸管吸収評価, 日本薬剤学会第36年会, May 2021.
148.	MARUYAMA Atsuya, Hidenori ANDO, 中江崇, 三輪泰司, 濱本英利, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : イオン液体を用いた難経口吸収性化合物の腸管吸収促進効果の検討, 日本薬剤学会第36年会, May 2021.
149.	UEDA Hiro, Haruka Takata, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 全身性エリテマトーデスモデルマウス由来マイクロパーティクルにおけるプロテオーム解析, 日本薬剤学会第36年会, May 2021.
150.	Yoshino Kawaguchi, Mizuki Awata, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 細胞ワクチンへの応用を目指した補体受容体標的化キャリアを用いる新規B細胞抗原刺激法の確立, 日本薬剤学会第36年会, May 2021.
151.	Yoshino Kawaguchi, Mizuki Awata, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 効果的な細胞免疫療法の開発に向けたB細胞への新規抗原刺激法の有用性評価, 日本薬剤学会第36年会, May 2021.
152.	Nehal Ali Emam Elsadek Emam Elhewan, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administer, 日本薬剤学会第36年会, May 2021.
153.	Hidenori ANDO and Tatsuhiro Ishida : 臨床実用を志向した腹腔内投与型核酸製剤の開発, 日本薬剤学会第36年会, May 2021.
154.	Shunto Yamamoto, Sesshu Yamaguchi, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 抗原封入リポソームの脾臓免疫による抗原特異的IgGの誘導とサブクラス多様性の評価, 日本薬剤学会第36年会, May 2021.
155.	Rina Yamade, Naoki Hirakawa, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 効率的な体液性免疫誘導に向けたアルブミンナノキャリアの開発, 日本薬剤学会第36年会, May 2021.
156.	Takaaki Matsuzaki, Taro Shimizu, Hidenori ANDO, Yu Ishima, 三輪泰司, 濱本英利 and Tatsuhiro Ishida : 経皮吸収型がんペプチドワクチンによるE.G7-OVA担がんマウスにおける腫瘍成長抑制効果, 日本薬剤学会第36年会, May 2021.
157.	Masaki Takata, Shunsuke Akagi, Hidenori ANDO, Taro Shimizu, Yu Ishima, 松島得雄, 草野貴友 and Tatsuhiro Ishida : 菌由来セルロースナノファイバーを用いた細胞の三次元培養と機能性評価, 日本薬剤学会第36年会, May 2021.
158.	Riku Uehara, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 重曹経口投与による腫瘍酸性環境の中性化とDoxil®の抗腫瘍効果の増強, 日本薬剤学会第36年会, May 2021.
159.	Sesshu Yamaguchi, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 新規脾臓免疫法による特異抗体の誘導とその多様性および結合親和性の評価, 日本薬剤学会第36年会, May 2021.
160.	Yuki Matsugi, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : マレイミド-チオール結合を介した抗がん剤封入リポソームの脾臓細胞への搭載とそのがん細胞障害性の評価, 日本薬剤学会第36年会, May 2021.
161.	Reon Kuramoto, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : エクソソームの脾臓免疫で得た抗血清(ポリクローナル抗体)の結合性評価, 日本薬剤学会第36年会, May 2021.
162.	FUKUDA Yuka, 中島祟樹, Yu Ishima, Hidenori ANDO, Taro Shimizu, 長野一也, 柴田寛子 and Tatsuhiro Ishida : PEG修飾タンパクの凝集体形成が及ぼす抗PEG抗体産生・血中滞留性への影響, 日本薬剤学会第36年会, May 2021.
163.	Chika Sakamoto, Taro Shimizu, Hidenori ANDO, Yu Ishima, 小林勝則, 石橋賢樹, 三輪泰司, 濱本英利 and Tatsuhiro Ishida : 経皮送達可能なsiRNA含有イオン液体製剤による新規乾癬治療, 日本薬剤学会第36年会, May 2021.
164.	Shunsuke Akagi, Hidenori ANDO, 田島健次, 松島得雄, 草野貴友, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 物性の異なるナノフィブリル化バクテリアセルロースを用いた新規PTX製剤の開発と腹膜播種治療評価, 日本薬剤学会第36年会, May 2021.
165.	Haruka Takata, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 核酸搭載PEG修飾リポソームが全身性エリテマトーデスの発症時期，増悪に与える影響, 日本薬剤学会第36年会, May 2021.
166.	Maichi Hama, Yu Ishima, Hidenori ANDO, Taro Shimizu and Tatsuhiro Ishida : アルブミン結合型パクリタキセル製剤AbraxaneⓇの変性アルブミン受容体を介した薬物輸送メカニズム, 日本薬剤学会第36年会, May 2021.
167.	Sherif Abdallah Emam Emam, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : Cell-type tropism promotes the intratumor accumulation of PEGylated cancer cell-derived exosomes, 日本薬剤学会第36年会, May 2021.
168.	茂木啓佑, 平尾彩香, 阿部礼奈, 森戸克弥, 髙山健太郎, Yusuke Doi, Hidenori ANDO, Tatsuhiro Ishida and 長澤一樹 : Oxaliplatinのpolyethylene glycol(PEG)修飾リポソーム製剤化による甘味感受性への影響, 日本薬学会第141年会, Mar. 2021.
169.	Ryuto Nakano, Naoki Hirakawa, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 難溶性薬物に対する溶解補助及び動態改善を企図した新規アルブミンナノ粒子の開発, 日本薬学会第141年会, Mar. 2021.
170.	Reon Kuramoto, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : エクソソームの脾臓免疫により誘導した抗体のエクソソームタンパク質への結合評価, 日本薬学会第141年会, Mar. 2021.
171.	Kohga Miyahara, Taro Shimizu, Hidenori ANDO, Yu Ishima, Szebeni Janos and Tatsuhiro Ishida : 高用量PEG修飾リポソーム投与時の抗PEG抗体誘導抑制機序に関する検討, 日本薬学会第141年会, Mar. 2021.
172.	Yoshino Kawaguchi, Yuna Shimazaki, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 脾臓B細胞上の補体受容体を介した抗原送達法を利用する新規細胞免疫療法の開発, 日本薬学会第141年会, Mar. 2021.
173.	Nana Matsuo, Yu Ishima, Mayumi Ikeda, Hidenori ANDO, Taro Shimizu and Tatsuhiro Ishida : 活性イオウ付加アルブミンの設計と還元ストレス誘導による抗腫瘍効果の評価, 日本薬学会第141年会, Mar. 2021.
174.	Sesshu Yamaguchi, Hidenori ANDO, Yuna Shimazaki, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 抗原封入リポソームの脾臓免疫で誘導された抗体の多様性・親和性評価, 日本薬学会第141年会, Mar. 2021.
175.	Rina Yamade, Naoki Hirakawa, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : ヒト血清アルブミン(HSA)を利用した脾臓への抗原送達による体液性免疫の誘導, 日本薬学会第141年会, Mar. 2021.
176.	Takaya Sunami, Hidenori ANDO, Atsuya Maruyama, 三輪泰司, 濱本英利, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : イオン液体を用いたGLP-1受容体作動薬の腸管吸収性検討, 日本薬学会第141年会, Mar. 2021.
177.	Hidenori ANDO : 新規3D培養基材を用いたがんスフェロイドの作成と応用評価, 第四回徳島大学統合的がん創薬研究クラスター合同オンラインミーティング, Mar. 2021.
178.	Hidenori ANDO : 抗原の脾臓送達を利用した新規抗体作製技術の基礎的評価, 徳島大学薬学部若手教員講演会, Jan. 2021.
179.	Hidenori ANDO : DDS抗がん剤の腫瘍内局在の解明と腫瘍微小環境改善による効果増強, 第59回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Dec. 2020.
180.	Sesshu Yamaguchi, Yuna Shimazaki, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 脾臓標的化リポソーム技術を用いた短期間で抗体を誘導する抗体産生誘導技術の開発, 第59回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Dec. 2020.
181.	Aina Mukai, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 致死性エンドトキシンショックに対するヒト血清アルブミンの治療効果, 第59回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Dec. 2020.
182.	Yuki Matsugi, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 脾臓細胞搭載抗がん剤封⼊カチオン性リポソームによるがん細胞障害性のin vitro評価, 第59回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Dec. 2020.
183.	Reina Hashimoto, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 皮膚角質中に含まれる活性イオウ分子種の検出, 第59回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Dec. 2020.
184.	Maki Sakai, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : ストレプトゾトシン誘発Ⅰ型糖尿病モデルマウスにおける血清活性イオウ分子の変動, 第93回日本生化学会大会, Sep. 2020.
185.	Hiroki Osafune, Mayumi Ikeda, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 生体液中の活性イオウ分子種含有タンパク質の同定と生理学的意義の解明, 第93回日本生化学会大会, Sep. 2020.
186.	Yuki Matsugi, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 抗がん剤搭載脾臓細胞によるがん細胞障害性評価に関する検討, 第36回日本DDS学会学術集会, Aug. 2020.
187.	Chika Sakamoto, Taro Shimizu, Hidenori ANDO, Yu Ishima, 小林勝則, 石橋賢樹, 三輪泰司, 濱本英利 and Tatsuhiro Ishida : イオン液体を用いたsiRNAの経皮送達による新規乾癬治療法の開発, 第36回日本DDS学会学術集会, Aug. 2020.
188.	Yoshino Kawaguchi, Mizuki Awata, Yuna Shimazaki, Chihiro Yoshioka, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : ヒドロキシ末端PEG修飾リポソームによる抗原刺激を利用した新規B細胞ワクチンの開発, 第36回日本DDS学会学術集会, Aug. 2020.
189.	Sesshu Yamaguchi, Yuna Shimazaki, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 脾臓辺縁帯B細胞への抗原送達による抗体産生誘導技術の開発, 日本薬剤学会第35年会, May 2020.
190.	MARUYAMA Atsuya, Hidenori ANDO, 三輪泰司, 濱本英利, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : インドシアニングリーンを用いたイオン液体の腸管吸収促進効果の検討, 日本薬剤学会第35年会, May 2020.
191.	Maichi Hama, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : アルブミン結合型パクリタキセル製剤であるAbraxane®の新たな腫瘍移行機序の発見, 日本薬剤学会第35年会, May 2020.
192.	Atsuya Maruyama, Hidenori ANDO, 三輪泰司, 濱本英利, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : イオン液体によるインドシアニングリーンの経口吸収性改善の検討, 日本薬学会第140年会, Mar. 2020.
193.	Yoshino Kawaguchi, Mizuki Awata, Yuna Shimazaki, Chihiro Yoshioka, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 細胞ワクチン療法への利用に適したB細胞サブセットの同定に関する検討, 日本薬学会第140年会, Mar. 2020.
194.	Maichi Hama, Yu Ishima, Hidenori ANDO, Taro Shimizu and Tatsuhiro Ishida : アルブミン結合型パクリタキセル製剤であるAbraxane®の新たな腫瘍移行機序の発見, 日本薬学会第140年会, Mar. 2020.
195.	Maki Sakai, Mayumi Ikeda, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 糖尿病患者血清におけるサルフェン硫黄の変動, 日本薬学会第140年会, Mar. 2020.
196.	Hiroki Osafune, Mayumi Ikeda, Maki Sakai, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : ヒト唾液α-amylase活性に及ぼすサルフェン硫黄の影響, 日本薬学会第140年会, Mar. 2020.
197.	Nanami Tasaka, Mayumi Ikeda, Taro Shimizu, Hidenori ANDO, Keiichiro Okuhira, Yu Ishima and Tatsuhiro Ishida : 毛髪キューティクルに存在するポリスルフィドの発見とイオウ供給による毛髪損傷抑制効果の検討, 日本薬学会第140年会, Mar. 2020.
198.	Shunsuke Akagi, Hidenori ANDO, 松島得雄, 草野貴友 and Tatsuhiro Ishida : 新規セルロースナノファイバーゲルを用いた3次元培養法の開発, 第19回日本再生医療学会総会, Mar. 2020.
199.	Chika Sakamoto, Taro Shimizu, Hidenori ANDO, Yu Ishima, 小林勝則, 石橋賢樹, 三輪泰司, 濱本英利 and Tatsuhiro Ishida : siRNA含有イオン液体製剤の経皮送達による乾癬治療, 第58回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2019.
200.	Hiro Ueda, Haruka Takata, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 全身性エリテマトーデス病態時の脾臓免疫細胞によるマイクロパーティクルの取り込み変化の検討, 第58回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2019.
201.	Shunsuke Akagi, Hidenori ANDO, 田島健次, 松島得雄, 草野貴友 and Tatsuhiro Ishida : 物理化学的性質の異なるナノフィブリル化バクテリアセルロース(NFBC)を用いたPTX製剤の開発とがん治療評価, 第58回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2019.
202.	Shunsuke Akagi, Hidenori ANDO, 田島健次, 松島得雄, 草野貴友 and Tatsuhiro Ishida : 両親媒性ナノフィブリル化バクテリアセルロース(Fibnano)の放出制御型がん治療製剤への応用, セルロース学会第26回年次大会, Jul. 2019.
203.	Hidenori ANDO : ナノフィブリル化バクテリアセルロースのがん治療への応用, 産業技術総合研究所ナノセルロースフォーラム第15回セミナー, Jul. 2019.
204.	Hiro Ueda, Haruka Takata, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : マイクロパーティクルによる抗体産生誘導は全身性エリテマトーデスの症状進行に関与する, 第35回日本DDS学会学術集会, Jul. 2019.
205.	Yuna Shimazaki, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : 脾臓への抗原デリバリー技術を利用した新規抗体産生技術の開発, 第35回日本DDS学会学術集会, Jul. 2019.
206.	Nanami Tasaka, Mayumi Ikeda, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 毛髪ケラチン中に存在するポリスルフィドの酸化ストレス応答, 第72回日本酸化ストレス学会学術集会, Jun. 2019.
207.	Arata Inoue, Yu Ishima, Mayumi Ikeda, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : 細胞培養系における血清アルブミン結合sulfane sulfurの役割, 第19回日本NO学会学術集会, Jun. 2019.
208.	Mayumi Ikeda, Yu Ishima, Maki Sakai, Taro Shimizu, Hidenori ANDO, 渡邊博志, 丸山徹, 小田切優樹 and Tatsuhiro Ishida : ヒト血清アルブミンに存在するポリスルフィドによるユニークな酸化ストレス応答, 第19回日本NO学会学術集会, Jun. 2019.
209.	Shota Fujimoto, Naoki Muguruma, Michiyasu Nakao, Hidenori ANDO, Yoshihiko Miyamoto, Koichi Okamoto, Yasushi Sato, Tatsuhiro Ishida, Shigeki Sano and Tetsuji Takayama : 新規蛍光プローブIndocyanine green (ICG) 標識Dasatinibを用いた消化管間質腫瘍 (GIST) の近赤外蛍光イメージング., 第14回日本分子イメージング学会総会・学術集会, May 2019.
210.	Shunsuke Akagi, Hidenori ANDO, 田島健次, 松島得雄, 草野貴友 and Tatsuhiro Ishida : 両親媒性ナノフィブリル化バクテリアセルロースを基剤とした放出制御型Paclitaxel製剤の開発, 日本薬剤学会第34年会, May 2019.
211.	Mayumi Ikeda, Yu Ishima, Taro Shimizu, Hidenori ANDO, Keiichiro Okuhira, 渡邊博志, 丸山徹, 小田切優樹 and Tatsuhiro Ishida : 血清アルブミンの酸化ストレス応答を模倣した新規抗酸化剤の設計, 日本薬剤学会第34年会, May 2019.
212.	Maho Tagami, Ai Ikeda, Hidenori ANDO, 江島清, 和田洋巳 and Tatsuhiro Ishida : 腫瘍内微小環境の改善によるDDS製剤の治療効果増強, 日本薬学会第139年会, Mar. 2019.
213.	Hidenori ANDO : 尿アルカリ化を指標とした腫瘍内環境の改善, 第2回徳島大学統合的がん創薬研究クラスター合同ミーティング, Feb. 2019.
214.	Maho Tagami, Hidenori ANDO, Li Shyh-Dar and Tatsuhiro Ishida : Continuous treatment with immune modulator can uniformize the effect of anti-tumor immunity, 第47回日本免疫学会学術集会, Dec. 2018.
215.	Yuna Shimazaki, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : Expansion of the delivering technique of PEGylated liposomes to marginal zone B cells for immunization with peptide antigen, 第47回日本免疫学会学術集会, Dec. 2018.
216.	Maki Sakai, Mayumi Ikeda, 今福匡司, Hidenori ANDO, Taro Shimizu, Yu Ishima, 丸山徹 and Tatsuhiro Ishida : 糖尿病患者における血清中サルフェン硫黄と抗酸化能の評価, 第57回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2018.
217.	Hiroki Osafune, Mayumi Ikeda, Maki Sakai, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 生体液に含まれる活性イオウ分子種の検出, 第57回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2018.
218.	Ai Ikeda, Hidenori ANDO, 江島清, 和田洋巳 and Tatsuhiro Ishida : 腫瘍内微小環境の改善にともなうDoxilの抗腫瘍効果増強, 第57回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2018.
219.	Hidenori ANDO, Takashi Mochizuki, Kenji Fujita, Kenji Tajima, Tokuo Matsushima, Takatomo Kusano and Tatsuhiro Ishida : Advanced application of nano-fibrillated bacterial cellulose (Fibnano®) to anti-cancer therapy, 第67回高分子討論会, Sep. 2018.
220.	Yu Ishima, Ryo Kinoshita, Mayumi Ikeda, Hidenori ANDO, Taro Shimizu, 小田切優樹, 丸山徹 and Tatsuhiro Ishida : ガス状リガンドと相互作用するヒト血清アルブミンの臨床応用, 第1回超分子薬剤学FGシンポジウム, Sep. 2018.
221.	Hidenori ANDO, Takashi Mochizuki, Kenji Fujita, 田島健次, 松島得雄, 草野貴友 and Tatsuhiro Ishida : ナノフィブリル化バクテリアセルロース(Fibnano)を用いた新規パクリタキセル製剤の開発とがん治療への展開, セルロース学会第25回年次大会, Jul. 2018.
222.	Rie Matsuoka, Hidenori ANDO and Tatsuhiro Ishida : 胃がん腹膜播種モデルにおいて腹腔内投与したカチオン性リポソームは腫瘍に選択的に集積する, 第34回日本DDS学会学術集会, Jun. 2018.
223.	Ai Ikeda, Ryo Kinoshita, Hidenori ANDO, 江島清, 和田洋巳 and Tatsuhiro Ishida : がん細胞の代謝特異性を利用したドキソルビシンのがん細胞内送達法の開発, 第34回日本DDS学会学術集会, Jun. 2018.
224.	Takashi Mochizuki, Hidenori ANDO, Kenji Fujita, 田島健次, Yu Ishima and Tatsuhiro Ishida : ナノファイバーバイオセルロースを用いた新規パクリタキセル製剤の開発, 日本薬学会第138年会, Mar. 2018.
225.	Tatsuhiro Ishida and Hidenori ANDO : 新規RNAi薬剤体腔内投与による難治がん治療法の開発, 遺伝子・デリバリー研究会第17回夏期セミナー, Sep. 2017.
226.	Rie Matsuoka, Hidenori ANDO and Tatsuhiro Ishida : 腹腔内投与カチオン性リポソームの動態評価と胃がん腹膜播種治療における有用性に関する検討, 第26回DDSカンファランス, Sep. 2017.
227.	Takashi Mochizuki, Hidenori ANDO, Kenji Fujita, 田島健次 and Tatsuhiro Ishida : 胃がん腹膜播種治療におけるナノファイバーバイオセルロースの応用に関する検討, 第33回日本DDS学会学術集会, Jul. 2017.
228.	Noriaki Minakawa, Noriko Saito-Tarashima, Tomoki Takahashi, Seigi Yamamoto, Nozomi Kinjoh, Hidenori ANDO, Tatsuhiro Ishida and Kentaro Kogure : 化学修飾DNAを利用したRNA創薬, 第33回日本DDS学会学術集会, Jul. 2017.
229.	Emam Emam Abdallah Sherif, Hidenori ANDO and Tatsuhiro Ishida : A novel strategy to increase the yield of exosomes, 日本薬剤学会第32年会, May 2017.
230.	Shota Fujimoto, Naoki Muguruma, Yoshihiko Miyamoto, Michiyasu Nakao, Shigeki Sano, Hidenori ANDO, Tatsuhiro Ishida and Tetsuji Takayama : KIT分子を標的としたGISTの分子イメージング, 第103回日本消化器病学会総会, Apr. 2017.
231.	Takashi Mochizuki, Hidenori ANDO, Kenji Fujita, 田島健次 and Tatsuhiro Ishida : ナノファイバーバイオセルロースの腹腔内がん化学療法への応用に関する検討, 日本薬学会第137年会, Mar. 2017.
232.	Rie Matsuoka, Hidenori ANDO and Tatsuhiro Ishida : 胃がん腹膜播種治療における腹腔内投与カチオン性リポソームの有用性に関する検討, 第55回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2016.
233.	Shinya Kobayashi, Hidenori ANDO, Emam Emam Abdallah Sherif, Tatsuhiro Ishida and Kazuyoshi Kawazoe : Doxorubicin投与による血清中Exosome分泌変化に関する検討, 第55回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2016.
234.	Rie Matsuoka, Hidenori ANDO and Tatsuhiro Ishida : 新規胃がん腹膜播種治療開発のためのカチオン性リポソーム腹腔内投与の有用性探索, ナノライフサイエンス・オープンセミナー2016, Sep. 2016.
235.	柏木美咲, 西田健太朗, 柴俊輔, 室木究, 大石晃弘, Yusuke Doi, Hidenori ANDO, Tatsuhiro Ishida and 長澤一樹 : オキサリプラチン封入PEG修飾リポソーム製剤投与ラットの後肢皮膚組織における白金蓄積及び手足症候群様症状の評価, ナノライフサイエンス・オープンセミナー2016, Sep. 2016.
236.	Hidenori ANDO, Masao Tanaka and Tatsuhiro Ishida : 大型放射光施設(SPring-8)における蛍光X線分析法を用いたオキサリプラチン腫瘍内分布の分析, 第25回DDSカンファランス, Sep. 2016.
237.	Hidenori ANDO, Lila Selim Ahmed Ali Abu Amr, Chihiro Katoh, 福島正和, 黄政龍, 和田洋巳 and Tatsuhiro Ishida : 核酸複合体(DFP-10825)の胸腔内直接投与を介した悪性胸膜中皮腫治療, 第32回日本DDS学会学術集会, Jul. 2016.
238.	Emam Emam Abdallah Sherif, Hidenori ANDO, Lila Selim Ahmed Ali Abu Amr, M.A. Mahmoud, G.S. Fakhr-eldin and Tatsuhiro Ishida : Interaction of cancer cells with liposomes; the extent of exsosome release, 第32回日本DDS学会学術集会, Jun. 2016.
239.	Rie Matsuoka, Hidenori ANDO, 前田典之 and Tatsuhiro Ishida : 胃がん腹膜播種治療のためのDDSキャリア腹腔内投与後の動態検討, 第32回日本DDS学会学術集会, Jun. 2016.
240.	Nozomi Kinjoh, Hidenori ANDO, Noriko Saito-Tarashima, Noriaki Minakawa and Tatsuhiro Ishida : 悪性胸膜中皮腫治療における新規shRNA発現化学修飾核酸の有用性の検討, 日本薬剤学会第31年会, May 2016.
241.	Hidenori ANDO, Sakiko Kobayashi, Lila Selim Ahmed Ali Abu Amr, 川添和義 and Tatsuhiro Ishida : ペメトレキセド封入カチオン性リポソームの胸腔内直接投与を介した悪性胸膜中皮腫治療, 日本薬剤学会第31年会, May 2016.
242.	Nozomi Kinjoh, Hidenori ANDO, Noriko Saito-Tarashima, Noriaki Minakawa and Tatsuhiro Ishida : Intelligent shRNA expression deviceのin vitro, in vivoにおける有用性評価, 日本薬学会第136年会, Mar. 2016.
243.	Takashi Mochizuki, Hidenori ANDO and Tatsuhiro Ishida : Doxil®及びオキサリプラチン封入リポソームの腹腔内投与の有用性に関する検討, ナノライフサイエンス・オープンセミナー2015, Feb. 2016.
244.	Nozomi Kinjoh, Hidenori ANDO, Noriko Saito-Tarashima, Noriaki Minakawa and Tatsuhiro Ishida : Intelligent RNA expression devise(iRed)による標的遺伝子抑制に関する検討, 第37回生体膜と薬物の相互作用シンポジウム, Nov. 2015.
245.	Takashi Mochizuki, Hidenori ANDO and Tatsuhiro Ishida : 抗がん剤徐放性製剤の腹腔内投与の有用性に関する検討, 第54回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2015.
246.	Nami Watanabe, Hidenori ANDO and Tatsuhiro Ishida : 胃がん腹膜播種モデルにおけるオキサリプラチン封入リポソーム静脈内投与による腫瘍増殖抑制効果, 第31回日本DDS学会学術集会, Jul. 2015.
247.	Nozomi Kinjoh, Hidenori ANDO, Noriko Saito-Tarashima, Noriaki Minakawa and Tatsuhiro Ishida : 新規RNAi分子発現核酸デバイスのin vitro, in vivo有用性評価, 第31回日本DDS学会学術集会, Jul. 2015.
248.	Chihiro Katoh, Lila Selim Ahmed Ali Abu Amr, Hidenori ANDO and Tatsuhiro Ishida : 悪性胸膜中皮腫治療に向けたリポプレックスの胸腔内投与とその動態, 日本薬剤学会第30年会, May 2015.
249.	Nami Watanabe, Hidenori ANDO and Tatsuhiro Ishida : 胃がん腹膜播種動物モデルにおけるオキサリプラチン封入リポソームの治療効果に関する検討, 日本膜学会第37年会, May 2015.
250.	Nozomi Kinjoh, Hidenori ANDO, Noriko Saito-Tarashima, Noriaki Minakawa and Tatsuhiro Ishida : 新規RNAi分子発現核酸デバイスを用いた標的遺伝子発現抑制効果, 日本膜学会第37年会, May 2015.
251.	Nozomi Kinjoh, Hidenori ANDO, Noriko Saito-Tarashima, Noriaki Minakawa and Tatsuhiro Ishida : 胸腔内がん治療を目指した新規核酸デバイスの有用性評価, 遺伝子・デリバリー研究会第15回シンポジウム, May 2015.
252.	Noriko Saito-Tarashima, 小島孝光, Nozomi Kinjoh, Kazuhiro Furukawa, Hidenori ANDO, Tatsuhiro Ishida and Noriaki Minakawa : New strategy for suppression of gene expresstion using intelligent RNA expressing device (iRed), 日本化学会第95春季年会, Mar. 2015.
253.	Noriko Saito-Tarashima, 小島孝光, Nozomi Kinjoh, Kazuhiro Furukawa, Hidenori ANDO, Tatsuhiro Ishida and Noriaki Minakawa : Intelligent RNA expressing device (iRed)を利用した核酸創薬の新手法, 第32回メディシナルケミストリーシンポジウム, Nov. 2014.
254.	Chihiro Katoh, Lila Selim Ahmed Ali Abu Amr, Hidenori ANDO, Tatsuhiro Ishida and Hiroshi Kiwada : 悪性胸膜中皮腫治療のための核酸搭載カチオニックリポソームの胸腔内投与とその動態評価, 第36回生体膜と薬物の相互作用シンポジウム, Nov. 2014.
255.	Nami Watanabe, Hidenori ANDO and Tatsuhiro Ishida : 胃がん腹膜播種に対するナノキャリアを用いた新規投与経路の検討, 第53回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2014.
256.	Nozomi Kinjoh, Hidenori ANDO, Noriko Saito-Tarashima, Noriaki Minakawa and Tatsuhiro Ishida : Intelligent RNA expressing devise(iRed)の細胞内導入による標的遺伝子抑制, 第53回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2014.
257.	Nami Watanabe, Hidenori ANDO and Tatsuhiro Ishida : 腹水を伴う腹膜播種における新規静注型治療法の確立, ナノライフサイエンス・オープンセミナー2014, Aug. 2014.
258.	Nozomi Kinjoh, Hidenori ANDO, Noriko Saito-Tarashima, Noriaki Minakawa and Tatsuhiro Ishida : Intelligent RNA expressing devise(iRed)のin vitroにおける標的遺伝子抑制に関する検討, ナノライフサイエンス・オープンセミナー2014, Aug. 2014.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

感染神経伝播型EV融合Nose-to-Brainミセルによる脳感染神経特異的RNA送達への挑戦 (Project/Area Number: 24K22407 )
膜タンパクに対する抗体を誘導するエキソソームの脾臓免疫技術の基盤構築と応用研究 (Project/Area Number: 24K02194 )
イオン液体を用いた中分子医薬品の革新的・非侵襲的吸収促進技術の開発 (Project/Area Number: 23K17477 )
人工高分子PEGに対する生体防御反応の解明と統合的理解 (Project/Area Number: 23K28428 )
高活性抗体の誘導を実現する抗原発現エキソソームの脾臓免疫技術基盤の構築 (Project/Area Number: 21H02644 )
Enhanced absorption drug delivery system by ionic liquid (Project/Area Number: 20K21898 )
PEG修飾タンパクによるアナフィラキシー誘導機構の解明とその制御に関する研究 (Project/Area Number: 19KK0279 )
Enhancement of conventional chemotherapy by treatment with an alkalinizing agent (Project/Area Number: 19K16415 )
Efficient anticancer drug delivery using a network structure of nanocellulose with a super high aspect ratio (Project/Area Number: 19H02549 )
Effects of anti-cancer drugs on secretion of tumor-related exosomes and its application for cancer treatment (Project/Area Number: 16K18861 )
Study of immunological response to nucleic acid delivery system (Project/Area Number: 15H04639 )
Development of novel cancer therapy via direct injection of DDS therapeutics into body cavity (Project/Area Number: 26893174 )
Search by Researcher Number (00735524)

Associate Professor : ANDO, Hidenori

Research

Personal Web Page

Field of Study

Subject of Study

Book / Paper

Book:

Academic Paper (Judged Full Paper):

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)